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SUMMARY.
A micro-neutralisation test for the detection of 
Coxsackie B specific antibody in patients serum is 
described. Patients with suspected cardiac and other 
illnesses with possible Coxsackie B virus etiology 
were examined. In 1983 34%. had titres of >256, in the 
better selected patients tested in 1984 the figure was 
46%
In the absence of virus isolation or the 
detection of significant rising titres the 
interpretation of static neutralising titres is both 
difficult and controversial. Detection of specific IgM 
in such patients, implying recent infection, appeared 
to be a possible answer to this problem.
A u - antibody capture enzyme linked immuno­
sorbent assay(ELISA) for the detection of Coxsackie B 
specific IgM antibody is described. This assay can 
readily be used for testing large numbers of sera and 
has the advantage over neutralisation tests in that a 
positive result represents recent or active infection.
A regimen for the serological diagnosis of 
Coxsackie B virus infections using this ELISA as a 
screening test followed by neutralisation tests to 
confirm the positive results was introduced. Seven 
hundred and sixty patients and 304 healthy adult 
controls were tested. The percentage positive by
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ELISA in each of the clinical categories of 
myopericarditis(33%), chest pain(22%), myalgic 
encephalomyelitis(31%), myalgia/Bornholm(19%) and 
pontrols(9%) was similar to that reported when 
Neutralisation tests alone were used, although results 
feor the individual patient may be different.
The duration of detection of CBV IgM in each of 
the clinical categories was measured. In acute 
illness such as Bornholm disease the CBV IgM was 
detected for 1 ^ 2  months, in myopericarditis for 3 - 6  
months. Persisting CBV IgM was detected for more than 
one year in some patients with M.E.
Cross reactions in this CBV IgM ELISA were 
investigated. Heterotypic responses were observed 
from patients with hepatitis A infections and in those 
With proven systemic Coxsackie A virus and echovirus 
infections. No cross reactions were observed in sera
Ci
from the 5 cases of poliovirus infections investigated. 
The exploitation of these cross-reactions in the rapid 
diagnosis of aseptic meningitis, a major cause of which 
bre enteroviruses is reported.
S?brty five patients with suspected aseptic meningitis 
Were investigated. A total of 10(22%) patients had an 
bnterovirus isolated from the CSF(6), faeces(4) or 
both(6). Thirty(67%) were found to have enterovirus 
specific IgM in their serum, including all 10 patients
from whom an enterovirus was isolated. Twenty one
if\ x,
patients were confirmed as having clinically diagnosed 
aseptic meningitis, 18(86%) of these were positive in 
the CBV IgM ELISA.
Two major differences in the CBV IgM response 
between patients with aseptic meningitis and those with 
cardiac and other illnesses of suspected CBV aetiology 
were noted. Firstly, a higher frequency of 
heterotypic reactions were observed, and secondly, 
stronger positive CBV IgM responses were detected more 
often in the aseptic meningitis patients.
CHAPTER 1
INTRODUCTION.
Historical background.
The name Picornavirus was proposed by the 
Enterovirus Study Group and accepted by the 
International Nomenclature Committee (1963) to 
designate a group of agents including the following:- 
A. Picornaviruses of human origin.
1. Enteroviruses *
a). Polioviruses 1-3.
b). Coxsackie A viruses 1-22, 24.
c). Coxsackie B viruses 1-6.
d). Echoviruses 1-9, 11-27, 29-34. 
e). Enteroviruses 68-72.
2. Rhinoviruses.
* Enteroviruses.
This subgroup was named in 1957 by the Committee 
on the Enteroviruses, National Foundation for Infantile 
Paralysis,(1) to bring together polioviruses, Coxsackie 
viruses and echoviruses, all viruses for which the 
human alimentary tract is the natural habitat.
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Although a crippling disease retrospectively 
recognisable as paralytic poliomyelitis appears in 
records of early antiquity, it began to be described as 
a clinical entity only in the late 1700's and early 
1800's. It became the subject of intensive study only 
after increasingly severe epidemics ocurred in Europe 
and North America.
Experimental work became possible following the 
successful transmission of the disease to monkeys in 
1908 by Lansteiner and Popper.(2). During the next 
forty years it was shown that the virus was regularly 
present in the stools of patients, that subhuman 
primates could be infected by the alimentary route, and 
that strains could be adapted to growth in laboratory 
rodents, permitting an expansion of laboratory studies. 
Significant antigenic differences among poliovirus 
strains were documented, resulting in their initial 
separation into three serological types.
The discovery by Enders et al(1949) (3) of 
poliovirus proliferation in primate cells of non neural 
origin did much to facilitate the study of the 
enteroviruses. Prior to this, virus isolations were 
slow, expensive and difficult. More frequently than 
not at this time, clinical symptomatology rather than 
specific aetiology contributed to the diagnosis of 
particular diseases, poliomyelitis included.
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In 1948, during the investigation of a 
poliomyelitis outbreak in the town of Coxsackie in New 
York State, viruses isolated from the faeces of two 
children were found to induce paralysis in newborn mice 
and hamsters (4). The isolation of further viruses 
with similar properties was soon reported (5 & 6). 
Pathogenicity for newborn mice was used to define this 
new group of viruses which were named Coxsackieviruses. 
The group was later divided into group A (24 serotypes) 
and group B (6 serotypes) Coxsackieviruses.
Following the introduction of in vitro cell 
cultures many new viruses were isolated from faecal 
material. It became clear that some of these isolates 
were neither polioviruses nor Coxsackieviruses since 
they differed in respect of both serology and 
pathogenicity for newborn mice. At first they lacked 
an association with any specific disease and were thus 
described as Orphan viruses, and in 1955 were given the 
acronym ECHOviruses, derived from the description 
Enteric Cytopathogenic Human Orphan.
Of the 33 serotypes assigned to this group, type 10 was 
reclassified as reovirus type 1, and type 28 was found 
to be a rhinovirus. Echovirus type 9 was found to be 
identical to Coxsackie A virus 23.
The difficulties of assigning new enteric 
picornaviruses to one of the four groups led to the
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recomendation that new enterovirus serotypes should be 
given numbers only (7). To date five new enterovirus 
serotypes have been accepted and designated enterovirus 
68 to 72.
In the current classification, enteroviruses are 
accorded generic status within the Picornaviridae 
Family as are rhinoviruses and a number of animal 
picornaviruses.
Characteristics of Enteroviruses.
The enteroviruses share many clinical, 
epidemiological, physical and biochemical features.
Typically enteroviruses are small 20-27 nM 
icosahedral particles containing a single molecule of 
single stranded ribonucleic acid (RNA) enclosed in a 
protein coat made up of four distinct polypeptides 
designated viral protein (VP) 1 ,VP2, VP3, and VP4.
The virions are non enveloped, resistant to lipid 
solvents such as ether and to inactivation by low pH.
Viral replication occurs in the cytoplasm of 
infected cells, with the viral RNA acting as a single 
polycistronic molecule of messenger RNA (mRNA) 
translated into a single protein which is subsequently 
cleaved to give the four structural proteins and thus 
purified RNA is infectious in its own right. Following 
replication mature progeny virus particles are 
released by lysis of the infected cell.
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The non-polio enteroviruses (NPEV) have been 
divided into groups based upon their initial 
pathogenicity for newborn mice, viz.:- 
Group A Coxsackieviruses (CAV) typically produce 
lethal paralysing infections with severegeneralised 
myositis of skeletal muscle.
Group B Coxsackieviruses (CBV) produce scattered focal 
myositis, but more severe damage to the nervous system, 
brown fat, pancreas and other viscera including the 
heart.
Echoviruses(EcV) are, by definition, nonpathogenic for 
newborn mice.
Although this form of classification has held up 
remarkably well for 30 years it has now been replaced 
by a numbering system, with new viruses of the 
enterovirus (EV) genus being numbered from 68 onwards.
Enteroviruses are transmitted most frequently 
by the faecal - oral route, but in conditions of 
improving hygiene the respiratory route becomes more 
important and, indeed is a more sensitive route. They 
have been implicated in a wide range of diseases of man 
with a heterogenicity across the classic groupings.
For example, (a) paralytic poliomyelitis can be 
caused by CBVs, by some CAVs, most notably CAV type 7, 
rarely by some EcVs and also as a sequel to EV 7| 
infection.
r
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(b) Acute muscle disease (Bornholm disease) is mainly 
caused by CBV, sometimes by CAV and occasionally by 
EcV(especially Ecv type 6).
(c) Skin rash and oropharyngeal lesions (hand foot and 
mouth disease) are caused mainly by CAV (types 4,9 10 & 
16) but may also be caused by CBV (types 1-5) and EcV 
type 9.
(d) Acute upper respiratory infections can be caused by 
most EVs eg. (CAV type 21).
(e) Aseptic meningitis can be caused by most 
enteroviruses.
(f) Viral heart muscle disease is particularly 
associated with CBVs.
(g) Acute haemorrhagic conjunctivitis is associated 
with CAV type 24, and EV type 70.
(h) Acute, life threatening disseminated viral 
infection of neonates is associated with EcV types 7 
and 11.
be-
(i) Myalgic encephalomyelitis y\ associated with 
CBV(types 1-5).
(j) Less frequently, enteroviruses have been associated 
with hepatitis, pharyngitis and encephalitis.
Infection with an enterovirus is usually 
subclinical and until recently there was little 
evidence for persistent infections occurring in humans.
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Serology.
During the last ten years there has been an 
increase in direct antigen detection by immunological 
methods and in serological tests for the diagnosis of 
recent virus infection, as alternatives to virus 
isolation procedures. This change in emphasis has been 
due to a number of factors. There has been 
dissatisfaction with the time taken to isolate and 
identify viruses. Cell culture techniques are expensive 
in terms of staff time and resources, which , when at a 
premium, tend to be deployed in areas which have the 
most immediate impact on patient management.
This change in emphasis towards serology has 
also been seen in the diagnosis of enterovirus 
infections, for which virus isolation has been the 
cornerstone of diagnosis for many years. Serological 
tests, notably neutralising antibody studies on 
patients from whom an EV had been isolated from the 
gastrointestinal tract, had a role in determining the 
systemic nature of infections.
In the investigation of viral heart disease 
(myopericarditis), which is generally regarded as a 
late manifestation of Coxsackie B virus infection, 
patients presented at a time long after virus shedding
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had ceased and the detection of rising titres of 
antibody was unusual. In these cases association of a 
disease syndrome with a particular virus was made on 
the finding of elevated antibody titres. While this 
type of epidemiological evidence is useful in the wider 
context of virus-disease association, in individual 
patients it may give a misleading diagnosis as up to 8% 
of the well population have antibody levels of this 
magnitude to one or more CBV serotype.
This situation was far from ideal, so attention turned 
to the possibility of detecting enterovirus specific 
IgM in order to diagnose recent infection. Work in 
this field has centred on the group B 
Coxsackieviruses(CBV) since a) there are only six 
serotypes to contend with, and b) there was good 
epidemiological evidence of their association with 
serious disease of man, particularly heart disease.
The first test for CBV-specific IgM to be 
evaluated was based on immunodiffusion techniques (8 
& 9). Using high titre antigen preparations containing 
a mixture of intact and empty capsids, two distinct 
lines of precipitation were observed,one being IgM 
antibody precipitating intact virus and the second IgG 
reacting with empty capsid.
Initial studies (8) showed that this technique could be 
used for the detection of specific IgM to all CBVs
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except CBV2. IgM was found in the sera of 77 of 79 
patients from whom CBV1,3,4 or 6 had been isolated. It 
was noted that not all IgM antibody was homotypic for 
the virus isolated but that heterotypic reactions 
occurred in 22% of patients. CBV specific IgM was 
also found in 21/86 (24%) of patients with CNS disease 
from whom CBVs had not been isolated. The test was 
then used to detect the presence of CBV specific IgM in 
a group of 259 patients with pericarditis(148 cases), 
myocarditis(92 cases) and pleurodynia(19 cases) and a 
control group of 259 patients with a diagnosis of viral 
or mycoplasma pneumonia (8). CBV specific IgM was 
detected in 27%, 25%, 37% and 8% respectively in 
patients with pericarditis, myocarditis, pleurodynia 
and controls. The author noted that some sera reacted 
with more than one CBV. 80% gave monotypic reactions, 
16% reacted with two serotypes, and one serum reacted 
with each of serotypes 3, 4, & 5.
Minor et al(10) used the same basic principle 
in a counter-immunoelectrophoresis test in an attempt 
to improve the sensitivity and specificity of the test. 
Concentrated antigen was again required 
and it was found necessary to use recent CBV isolates 
rather than prototype strains which gave inconsistent 
results. Twenty nine patients from whom a CBV had
been isolated and who produced ^4-fold rise in
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neutralising antibody titres were tested. Twenty(69%) 
of these were positive for CBV IgM antibody; 19(65%) 
produced a monotypic homologous response and one(CBV5 
isolate) a heterotypic response. Again, patients 
infected with CBV2 produced poorer results in this 
assay; only three of seven patients infected with this 
virus were positive and one of these exhibited a 
heterotypic reaction only. In controls studied at the
same time, 2(9%) of 22 patients from whom an Ecv or a
CAV had been isolated (both Ecv type 6) and one (2%) of
50 patients from whom a non-enterovirus had been
isolated were positive in this assay.
It has been suggested that these methods 
should have been exploited as routine diagnostic 
procedures. There are several reasons why this did not 
happen. 1) The preparation of high titre antigen on a 
regular basis for large numbers of tests made the test 
very expensive.
2) Current trends in routine diagnostic virology 
laboratories are towards enzyme immunoassays with all 
the attendant instrumentation, and staff are poorly 
motivated in relation to what is perceived as outdated 
technology. 3) The work load in laboratories using 
neutralisation tests was so large that the use of IEOP 
was not practicable.
In 1980 El-Hagrassy, Banatvala & Coltart (11)
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described a u-antibody capture enzyme-linked 
immunosorbent assay(ELISA) for the detection of CBV 
specific IgM. The antigen used was a pool of CBV 1-5 
antigens and each sample was also tested against 
normal(control) antigen; the result test was assessed 
on the difference between the two readings. Ten sera 
known to contain CBV IgM (by neutralisation tests on 
density gradient fractions) were all positive by this 
ELISA test. Ten of 12 (83%) sera from patients from 
whom a CBV had been isolated and/or showed a >4-fold 
increase in CBV neutralising antibody titres were also 
positive. As a control group 46 patients with recent 
infections other than CBV were tested, and none was 
found positive.
Dorries and ter Meulen(12 & 13) described an 
indirect solid phase radio-immunoassay (1980) and 
subsequently an ELISA (1983) for the detection of CBV 
specific IgM using individual antigens as opposed to a 
pooled virus . They found that the reactions of sera in 
their system gave three patterns of results, homotypic, 
type-predominant, and heterotypic. In the homotypic 
pattern sera gave a positive result with only one CBV 
serotype which was the same as that isolated. In the 
type-predominant group there was a strong reaction with 
the isolated serotype and weaker reactions against 
other serotypes. In the heterotypic response,
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moderate to strong positive reactions were found 
against all serotypes regardless of the isolated 
serotype.
On further investigation of their test the 
authors found that the antigens which they used 
contained a mixture of intact or native virions and 
incomplete pro-virions in the form of capsids of VPO 
(polypeptide precursor of VP2 & VP4), VP1 and VP3. 
Reactions of these separated polypeptides with sera 
showing homotypic and heterotypic responses indicated 
that both the type and group specific antigenic 
determinants were located on the VP1. These results 
are in agreement with many other workers who have shown 
that type specific reactions in serological tests for 
enteroviruses require the use of purified intact native 
virus. Dorries and ter Meulen also demonstrated a 
cross-reaction in their test with serum from a patient 
with an acute CAV 9 infection. This, with the report 
by Minor et al (10) of two cross-reacting sera from 
patients with Ecv 6 infections, were the first reports 
of cross -reactions with other members of the 
enterovirus group.
Morgan-Capner & McSorley (14) described a u- 
antibody capture radio-immunoassay (MACRIA) for the 
detection of CBV4 and CBV5 antibody. Their results, 
although on small numbers of sera, are interesting in
21
that they give further evidence of the occurrence of 
cross-reactions within the enterovirus group. Ten of 
20(50%) cases of CBV1,2,3,5 & 6 infections gave 
positive results in their CBV4 assay, and 7 of 18(39%) 
CBV1,2,3,4, & 6 infections reacted in the CBV5 assay. 
More significantly, 9 of 13(69%) cases from whom a CAV 
or EcV had been isolated gave a positive reaction in 
both the CBV4 and CBV5 assays.
From the foregoing it was quite clear that 
further work was required to develop the CBV IgM test 
for use in a routine diagnostic laboratory, and to 
determine the extent of, and the problems caused by, 
the apparent cross reactions and to find a solution to 
such problems. A further question might be added : 
could any detectable cross-reactions be used in a 
diagnostic manner?
The following chapters set out attempts to test these 
questions, and put forward a working hypothesis for the 
serological diagnosis of enterovirus infections in man.
22
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CHAPTER 2.
NEUTRALISATION TESTS.
Introduction.
The neutralisation test (NT) is at present 
the most commonly used technique for the serological 
diagnosis of Coxsackie B virus (CBV) infections. The 
test is based on the measurement of neutralising 
antibody in patients serum, i.e. antibody capable of 
inhibiting virus infectivity in vivo and in vitro.
Neutralising antibody appears early in the 
illness (0-3 days) reaching a peak after 14 days, and 
thereafter high levels of neutralising antibody may 
persist for months or years. Their decrease is not 
necessarily associated with recovery from the 
presenting illness ( 1, 2 ). Thus it is possible 
to diagnose a current infection by demonstrating a 
fourfold or greater rise in antibody titre between sera 
taken in the acute and convalescent phases of illness.
26
The majority of patients with suspected CBV 
infections present too late in their illness to 
demonstrate significant rises in neutralising antibody 
titre, and thus virus diagnosis depends on the 
interpretation of static high titres often in single 
serum samples. Grist et al (3), reported an 
association of high CBV titres with recent infection in 
their study of acute myocarditis and non-bacterial 
pericarditis. They regarded titres of £512 as 
diagnostically significant since only 4% of the sample 
of the healthy adult population sampled showed this 
level of antibody. Using this criterion they found 
that at least 33% of acute myocarditis and 14% of 
pericarditis cases were associated with a recent CBV 
infection.
This chapter presents the results obtained in 
1983-84 using NT for the serological confirmation of 
diagnosis of CBV infections in patients with suspected 
CBV associated viral heart disease.
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Neutralisation Tests.
1 Patients.
Blood samples from 2226 patients were tested 
in 1983 and from 1430 in 1984. The majority of these 
patients were located in the West of Scotland, the 
remainder in East Scotland and in various parts of 
England.
The clinical classification of patients into 
the various designated groups was based entirely on 
information provided by many clinicians on the request 
forms accompanying specimens. Because the numbers were 
too great and the sources so varied no routine follow - 
up enquiry was pursued.
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Materials and methods.
Cell cultures
(a) Vero cells.
Continuous African Green Monkey Kidney(ATCC N0 .CCL8I) 
were obtained from Flow Laboratories Ltd., Irvine, 
Scotland.The passage number varied in the sequential 
experiments.
(b) Media
The composition of the culture media (1-4) used for the 
growth and maintenance of the cell lines is shown in 
Table 2.1. The phosphate buffered saline(PBS) used 
throughout was Dulbecco A Saline without added calcium 
and magnesium (4,5).
(c) Preparation of cell cultures
Monolayers of Vero cells were grown in 120cm2 plastic 
tissue culture flasks (Nunc) in Medium No.l. Screw- 
capped flasks were incubated at 37°C and confluent 
monolayers were achieved in 2-4 days.
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Table 2.1.
CELL CULTURE MEDIA FOR NEUTRALISATION TESTS.
Constituents.
Medium No. EMEM FCS P+S MgCl2 199
1 100ml 5ml 1ml 0ml 0ml
2 100ml 5ml 1ml 1ml 0ml
3 100ml 0. 5ml 1ml 1ml 0ml
4 0ml 5ml 1ml 1ml 100ml
EMEM = Eagles minimum essential medium (Earle's salts)
with 2.5% NaHC03
FCS = Foetal calf serum.
P+S = Penicillin at lOOiu/ml plus streptomycin at 
lOOug/ml.
MgCl2 = 2M magnesium chloride.
199 = Medium 199.
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Sub-Cultivation.
Confluent monolayers of Vero cells were washed twice 
with sterile PBS. They were then flooded with a 
solution of 0.25%(1:250) trypsin/0.2% ethylene diamine 
tetra acetic acid(EDTA). After 1-2 minutes this 
solution was poured off and the flasks incubated at 
37°C until the cells became detached from the plastic 
(3-5 mins.). The detached cells were suspended in 10ml 
of medium No.l and mixed by aspiration until a single 
cell suspension was obtained. The cell suspension was 
reseeded into 120cm2 flasks at a "split11 ratio of 
l:4(i.e., 1 flask into 4 flasks), giving confluent 
monolayers in 2-4 days. Cells showing abnormal growth 
characteristics, such as very slow growth, or "stringy" 
appearance, proved unsuitable in the NT and were 
discarded.
(d) Preparation of cell suspension for the NT
Confluent monolayers of healthy Vero cells were washed 
and trypsinised as in (c) above. The cells were then 
resuspended in PBS (20 ml per donor flask) and 
centrifuged at 1500 rpm in a swing-out rotor on a bench 
centrifuge. The PBS was removed and the pellet of 
cells resuspended in medium No.2 (10 ml per flask ).
The cells from all the flasks were then pooled and a 
total and viable cell count made.
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(e) Cell count.
The cell suspension from (d) was diluted 1 in 10 in 
0.4% trypan blue stain. This is a supravital stain 
which is only taken up by dead cells within 2 minutes 
at room temperature. An improved Neubauer 
haemocytometer was charged with this and total and 
viable cell counts performed. An excess of dead 
cells (>10%) indicated that the cell suspension was 
unsuitable for use in the NT, though in practiee this 
was rare. The suspension was finally adjusted to give 
a concentration of 1.5 x 10s cells per ml in medium 
No.2. lOOul of this suspension was added to each well 
of the microtitre plates in the N.T.
PREPARATION OF VIRUS STOCKS.
(a) Source
Coxsackie B virus type 1, strain PO 49683
Coxsackie B virus type 2, strain Ohio - Red 50207
Coxsackie B virus type 3, strain Nancy 50531
Coxsackie B virus type 4, strain Dalldorf 51196
Coxsackie B virus type 5, strain 53112.
The above Coxsackie B viruses were donated by Dr. 
E.J.Bell, Regional Virus Laboratory, Ruchill Hospital, 
who received them from the Central Public Health 
Laboratory, Colindale, London. The viruses were 
passaged in primary primate cells, then adapted to grow 
in Vero cells at the Regional Virus Laboratory, Ruchill
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Hospital. 1
(b) Propagation-
CBV types 1-5 were grown in confluent monolayers of 
Vero cells in 120 cm2 tissue culture flasks. 0.5ml
J
of seed virus was added to approximately 50ml of Medium 
No.3. Confluent monolayers of Vero cells were washed 
once in PBS and 50ml of virus suspension was added to 
each flask. The flasks were then incubated at 37°C 
until all the cells exhibited a typical enterovirus 
cytopathic effect (CPE) in 2-3 days. The flasks were 
then frozen at -20°C and thawed, three times. The cell 
culture fluids were then centrifuged at 3000 rpm for 20 
min in a bench centrifuge to remove cellular debris.
The supernates were aliquoted in 0.5 ml volumes and 
stored at -20°C.
(c) Virus titration.
(i) Logarithmic dilutions of clarified suspension 
of CBV 1-5 from 10-1-10“8 in Medium No.4 were prepared.
(ii) 0.025 ml (25ul) of each virus dilution was 
added to one column of 4 wells commencing with the 
highest dilution on the right hand side of the plate.
(iii) 25 ul of Medium No.4 was added to each test 
well to represent and replace the serum dilution used 
in the neutralisation test. The plate was then covered 
with a loose lid and incubated at room temperature for 
90 mins.
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Figure.2.1
VIRUS TITRATION.
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CBV 5
Figure. 2.1. continued.
VIRUS TITRATION.
JLO-1 10‘2 10~3 IQ-4 10-5
'CiOH 10‘7 10
5 - + + + + + + +
6 + + + +  + + - -
7 + + + + + + - -
8 + + + + + + +
9 4 3 2 1
10 4 3 1 1
11 4 3 1 1
12 4 3 2 1
TTPHT. | cc>% 50% 25%
12.-5%
TCIDso 
=  107
+ = Cytopathic effect (cpe) 
- = No cpe (100% cells).
4 = Confluent cell layer.
3 = 75% confluency.
2 = 50% confluency.
1 = 25% confluency.
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(iv) 100 ul of Vero cells at a concentration of 1.5 x 
105 cells/ml in Medium No.2 was then added to each test 
well.
(v) Cell controls were prepared in quadruplicate 
wells, giving cell concentrations of 100%, 50%, 25% and
12.5 % of test cell suspension in medium No.2, and 50ul 
of medium No.4 was then added to each control well to 
replace the virus/serum mixtures volumes.
(vi) The microtitre plates were then sealed with 
non-toxic plate sealing tape (Titertek) and incubated 
at 37°C for 64-70 hours.
(vii) Each well of the microtitre plate was then 
examined microscopically for CPE using an inverted 
microscope (Olympus IMT-1) with a X 4 objective and X 
10 eyepieces.
(viii) Cell controls These were expected to
be confluent at 100% and 75% dilutions, half confluent 
at 25% and sparse at 12.5%.
(ix) Readings. Each well showing 1+ 
(approximately 10% of cells infected) or greater CPE 
was scored as positive. Those showing no CPE or 
microplaques only were scored as negative. The final 
dilution of virus was expressed as tissue culture 
infective dose 50 (TCID so), i.e., the concentration of 
virus capable of producing a 1+ or greater CPE, under 
these test conditions, in 50% of the inoculated
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cultures as calculated by Karber's formula 
TCID50 = L - d(S - 0.5), where: L = log1Q of the lowest 
dilution (-1 here)? d = log1D difference between each 
dilution (1 here) and S = sum of the positive results. 
The TCID50 for the 5 CBV serotypes varied from 10-3 - 10" 
7. In the neutralisation tests viruses were used at 
100 TCID50. (see Figure. 2.1).
Positive control sera.
(a) Source
Enterovirus typing sera raised in monkeys were used as 
positive control sera. These antisera were donated by 
Dr. E.J.Bell, who received them from the American Type 
Culture Collection, Maryland, USA. They had already 
been characterised and their homotypic and heterotypic 
neutralising titres estimated. Titres ranged from 
1/100 - 1/400.
(b) Standardisation of positive control sera.
Serial doubling dilutions of heat inactivated antisera 
from 1/20 - 1/1280 were prepared as follows:
(i) 25 ul of medium No.4 was added to two rows of 8 
wells for each antiserum in a flat well microtitre 
plate, and 25 ul of a 1/10 dilution of each antiserum 
in PBS, previously inactivated at 56°C for 30 mins, 
were added to the first pair of wells in each of 2 
rows. Using microtitre diluting loops (Titertek) the
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antisera were diluted through a series of seven wells, 
giving dilutions of 1/20 - 1/1280 in duplicate. The 
eighth well in each row held serum at a 1/20 dilution 
which served as a serum toxicity control.
(ii) 25 ul of CBV at 100 TCID5Q per 0.025ml in medium 
No.4 was added to each well of the serum titration, and 
25 ul of medium No.4 was added to the serum controls.
(iii) Virus controls at 100, 10, 1, and 0.1 TCIDso were 
set up at the same time. The plates were covered with 
a loose lid and incubated at room temperature for 90 
mins.
(iv) 100 ul of Vero cells at a concentration of
1.5 x 105 cells/ml in medium NO.2 were added to each 
well, including the virus controls.
(v) Cell controls at 100, 50, 25 and 12.5% were also 
set up. The plates were sealed with non toxic tape 
and incubated at 37°C for 64-70 hrs.
(vi) The plates were then examined microscopically for 
evidence of either virus growth or toxicity.
(c) Reading positive control serum titrations.
(i) Cell controls: 100% cell control needed to show 
a complete monolayer, with confluence gradually 
decreasing.
(ii) Virus controls: these should show virus
dilutions to be no more than one log1G step over or 
under the expected result.
(d) Antiserum. Providing the cell and virus controls 
are acceptable, the titre of the positive control serum 
is taken as the highest dilution of serum giving 
complete inhibition of viral CPE.
In the neutralisation test the positive control sera 
were double diluted from 4 times titre to 1/4 titre 
thus giving a measure of the sensitivity of the test.
(e) Patients sera.
Sera for testing were diluted 1/16 in PBS then 
inactivated at 56°C for 30 mins. These dilutions were 
normally stored overnight at 4°C before being tested.
The sera were then titrated for testing from 1/3 2 - 
1/512 giving final dilutions of 1/64 - 1/1024 in the 
serum/virus mixture.
Coxsackie Bl-5 Neutralisation Tests Proper
(a) Preparation of plates
Eight sera could be tested in duplicate against 
one virus on a single microtitre plate. Sera were 
normally tested in batches of 32 giving a total of 22 
plates, including 2 control plates, per batch. Serum 
controls at 1/64 were included in the CBV 1 plate.
Cell controls were included in all other plates to 
check for toxicity of the plate. In order to reduce 
the risk of cross contamination only one virus serotype 
was used on any one test plate, but were combined in 
the control plates.
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(b) Preparation of virus dilutions.
On the day before the test, virus dilutions 
containing 100 TCIDso were prepared in medium No.4, and 
further dilutions in 2 ml volumes at 10, 1 and 0.1 
TCID50 were also made. These were stored at 4°C prior 
to use.
(c) Protocol.
(i) Doubling dilutions of patients' sera from 
1/32-1/512 were made in medium No.4 in 25 ul volumes in 
flat bottom microtitre plates using microdiluter loops. 
Doubling dilutions of positive control sera for each 
virus from 4 times titre-1/4 titre were prepared in 
duplicate on a separate control plate.
(ii) 25 ul of virus at 100TCID5O was added to the 
appropriate test and control plates, and virus 
titrations at 100,10,1 and 0.1 TCID50 were also 
included.
(iii) Medium No.4 was added to the serum controls and 
to the virus titration to keep all volumes constant.
(iv) The plates were then incubated at room temperature 
for 90 minutes.
(v) 100 ul of Vero cells in medium No.2 at a 
concentration of 1.5 x 105 cells/ml were added to 
each test and control well. Cell controls containing 
100%, 50%, 25% and 12.5% dilutions of cells were also 
prepared, and 50 ul of medium No.4 was added to the
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wells of the cell controls to replace the serum/virus 
mixtures.
(vi) The plates were then sealed with non toxic plate 
sealing tape and incubated at 37°C for 64-70 hours.
(d) Reading the neutralisation test.
Each well was examined microscopically for evidence of 
virus growth.
(i) Cell controls.
The 100% must show a confluent cell monolayer, 
gradually reducing to show no more than a few plaques 
at 12.5%.
(ii) Virus controls.
These must show the strength of each virus to be no 
more than one log1G step over or under the expected 
result.
(iii) Positive serum controls.
These should be within one dilution step of the 
expected result. Those showing neutralisation titres 
one step lower than this when the virus control is at 
the highest acceptable level are regarded as readable 
and the patients7 serum titres adjusted accordingly.
If the virus is showing low infectivity and the 
positive serum controls do not show an end point then 
the test results are invalid.
(iv) Patients 7 sera.
All serum controls should show confluent monolayers.
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Occasionally, single wells may be toxic, giving the 
impression of virus growth, but if only one of the 
duplicate serum controls is toxic results were 
accepted. If both serum controls were toxic the serum 
was retested after further heat inactivation.
The end point of the patients' serum titration was
taken as the highest dilution giving complete
inhibition of viral CPE. This may be adjusted later by 
one dilution step either way depending on the results 
of the virus and positive serum controls.
Results.
Two relevant points of background information 
regarding the circulation of CBV in our community have 
already been established. Firstly there has been no 
major epidemic of CBV infection since 1965, when 
Coxsackie B5 was predominant both in Scotland and 
elsewhere in the United Kingdom (6,1). Secondly,
CBV antibody studies of normal population groups 
between 1973 and 1978 showed that 10% had titres of 256 
and 4% titres of £512 to one or more of the group B 
Coxsackieviruses (3J) , as revealed by recent studies in
1980-81 by O'Neil et al. (9). My own figures for 1984
in Table 2.3 indicate that this antibody status has 
remained relatively unchanged. The table lists the CBV
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serotypes isolated during 1983 and 1984, and shows it 
is not unusual for one serotype to predominate in any 
particular year. Bell and McCartney (^ ) listed the 
serotypes isolated in the same community in the years 
1972-1983 and although overall CBV types 4 and 2 were 
predominant there was no discernable pattern in the 
frequency of occurrence of any serotype.
Table 2.3 lists the total number of patients 
tested serologically in each of the two years and the 
percentage found positive by the criteria already 
given. The percentage positive for 1983, 34%, is 
similar to those recorded in previous years (7). In 
1984 this figure rises to 46%. The reason for this
i
apparent increase in positives in 1984 was that this 
laboratory was no longer able to cope with the 
escalating demands by clinicians for CBV serology. In 
order to reduce the number tested stricter criteria for 
the selection of patients for testing we^ imposed on 
clinicians. By this means the number of sera tested 
was reduced by over one third, and those selected were 
therefore more likely to produce a positive result.
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Table 2.2.
CBV ISOLATES 1983 - 1984.
B1 B2 B3 B4 B5 TOTAL
1983 10 0 1 3 0 13
1984 0 1 0 0 15 16
Table 2.3.
CBV SEROLOGY RESULTS 1983 - 1984.
% POSITIVE
No. of ANTIBODY TITRES OF: TOTAL %
patients .^512 256 .^256
1983 2222 17 17 34
1984 1430 27 18 46
Controls*
1984 87 5 12 17
* Sera obtained from healthy adults in the 
West of Scotland, and donated by the Scottish serum 
bank, Ruchill hospital.
Significant rising or falling titres (>4 fold) were 
found in only a few cases, in 6 in 1983 and 6 in 1984, 
most of whom had acute chest pain (pleurodynia) or 
acute myocarditis. This is not an unexpected result 
since cardiac disease is thought to be a late 
manifestation of viral infection (9, 10), but it 
indicates how difficult it is to obtain serum early 
enough to demonstrate significant rising antibody 
titres.
Table 2.4.
CBV serological results in various clinical 
categories 1983 - 1984.
1983 1984
TcrToL-
Clinical No. (%) (%) (%) No. (%) (%) (%)
category tested >512 256 >256 tested >512 256 >256
Myo/Per 313 18 14 32 352 33 22 55
C.P. 597 16 17 33 374 23 19 42
Mya/Bor 254 22 19 41 164 24 15 39
M.E. 389 16 24 40 210 35 15 50
Misc 682 12 14 26 330 22 20 42
Myo/Peri = Myopericarditis. 
Mya/Bor = Myalgia/Bornholm. 
Misc = Miscellaneous.
C.P. = Chest pain. 
M.E. = Myalgic - 
encephalomyelitis
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Since the beginning of the late 1970's, interest 
has concentrated on patients with suspected viral heart 
disease. These were predominantly males in the 40-60 
year age group. The results of studies on these 
patients, tested in 1983 and 1984, and classified on 
their admission diagnosis, are given in Table 2.4. 
Again, differences in the percentage positives between 
the two years are seen, particularly in the cardiac 
groups (myopericarditis and chest pain). The 1983 
figures are similar to those found in routine testing 
in the years 1975-82 (7). The 1984 figures are much 
closer to those found in a six year controlled study of 
cardiac patients (3), in which 42%, 33% and 13% were 
found to have titres of>256 in the chest pain, 
myocarditis and pericarditis groups respectively.
This difference between the 1983 & 1984 results is 
attributable to the better selection of patients rather 
than an increase in circulating CBV's in the community.
In 1980 there was a revival of interest in the 
possible viral aetiology of myalgic encephalo - 
myelitis (ME), previously known as Royal Free Disease
t '•
after the outbreak in that London hospital in 1975 (12.,
13). As a result the range of patients tested was 
widened to include those with such diverse 
symptomatology as general myalgia, chest pain with 
palpitations but without ECG changes, vertigo,
46
labyrinthitis, paraesthesia and extreme fatigue.
Requests for laboratory investigation of patients 
with non-cardiac disease now exceeded those with 
suspected cardiac illness. The percentage positives 
in the ME group with titres £256 were 40% in 1983 and 
50% in 1984, again reflecting the better selection of 
cases by clinicians. In our 1983 study of 54 well 
documented cases of ME. 59% were found to have titres 
of >256 (B) .
Selecting titres of >512 to one or more CBV, the 
most frequent response detected was to CBV 4 (Table 
2.5), which, over the preceding years, had been the 
serotype most frequently isolated, although not as 
often as the serological results might imply.The 
figures for 1984 reflect better the circulating 
viruses, with increases over 1983 in CBV 1, 3 and 5 
serotypes despite the fact that 33% fewer sera were 
examined. Since 1979 CBV 4 and, to a lesser extent, 
CBV 2 antibody responses have been those most commonly 
encountered (7). On the few occasions when a CBV was 
isolated, and paired acute and convalescent sera were 
available for study, the titre of the heterotypic 
antibody response equalled or even exceeded those of 
the homotypic antibody (Table 2.6). Thus in the 
absence of virus isolation, prediction of the infecting 
serotype in patients with multiple rising or static
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high titres is almost impossible.
Table 2.5.
Frequency of CBV serotype responses* 1983 -1984.
Dominant CBV 
serotype 
isolated in 
the comunity 
CBV 1.
CBV 5.
* = titres > 512.
Serotypes
Year B1 B2 B3 B4 B5
1983 18 134 17 255 3
1984 70 53 35 180 47
Table 2.6.
Examples of homotypic and heterotypic antibody 
to CBV infections.
Antibody titres in acute(A) 
Virus and convalescent(C) serum,
isolated CBV serotypes
Patient from faeces 1 B1 B2 B3 B4 B5
F26 years CBV 1 A <64 <64 <64 <64 <64
chest pain C 256 512 256 512 256
Ml3 years CBV 2 A <64 <64 <64 64 <64
sore tliroat C <64 >1024 >1024 64 <64
M25 years CBV 5 A <64 <64 <64 <64 <64
meningitis C <64 <64 <64 <64 256
Foot note.
The acute and convalescent sera were a minimum of 
7 days opart.
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Discussion.
The CBV microtitre neutralisation test permits the 
testing of large numbers of sera not possible by 
conventional tube culture methods. This test gives 
accurate reproducible results provided adequate cell, 
serum and virus controls are included. The main 
problems are associated with the virus sensitivity of 
the cell cultures which may change after repeated 
subcultivations, while cell lines, although 
theoretically capable of an infinite number of 
subcultures, generally become unusable after 30-40 
possibly due to mycoplasma infection from FCS or the 
experimenter/tissue culturist.
Antibody responses in the individual patient vary 
markedly and the clinician must interpret the 
virological results with careful regard to the 
patient's illness and onset date. Some patients may 
only achieve maximum titres of 128 (especially in the 
case of CBV 1, 3 and 5 serotypes), which fall short of 
the minimum "positive" level, and yet such titres may 
be relevant for such patients. In contrast, detection 
of high titres may be purely coincidental.
Heterotypic antibody responses cause similar problems. 
In these neutralisation tests it has been observed that 
high titres to CBV 4 and CBV 2 appear together 
regularly, and a similar but less frequent cross
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reaction was observed between CBV 1 and 3. CBV 5 
showed the highest frequency of monotypic response.
To some extent this phenomenon is due to cross 
reactions between common antigens on different viruses. 
Another explanation may be that because CBV 4 is 
dominant throughout the world, infection is acquired 
early in life with, or more often without, symptoms. 
Later infection with another CBV results in an 
anamnestic boost (recall) of the old CBV 4 antibody. 
This type of response is common in poliovirus and 
influenza virus infections.
In general, however, serological diagnosis based 
on high static titres have proved useful in clarifying 
the role of CBV in adult heart disease (^ , ‘i). The 
findings reported here have been confirmed 
independently by other investigators (£J^ 14).
The association of Coxsackie B viruses with 
certain adult heart diseasesis now well recognised. 
Other diseases, such as diabetes, pancreatitis and 
myalgic encephalomyelitis (ME), are now receiving 
closer scrutiny in respect of such an association.
A similar pathology to many of these illnesses is seen 
when mice are infected with the viruses , so an 
associated role in human disease would not be totally 
unexpected.
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Although serological testing for CBV neutralising
antibody is time consuming and its limitations in
respect of accurate virus diagnosis in the individual
patient are considerable, the demand by clinicians for
this service has increased annually. There is no
Some.
specific antiviral therapy available, but^patients, 
often adults in the 30-40 year age group who are struck 
down by an illness mimicking a heart attack or with 
debilitating ME, apparently derive considerable 
psychological benefit if a presumptive diagnosis of 
CBV infection is made. Clinicians report that such a 
virus diagnosis often prevents these patients from 
becoming cardiac or psychiatric "cripples" and that 
they accept their illness with a much more positive 
attitude. The fact that stable high neutralising
titres are so difficult to interpret, especially in 
chronic relapsing illnesses, has led to the postulation 
that detection of Coxsackie B specific IgM antibody 
would help in virological diagnosis for many patients. 
Detection of specific IgM in such patients implies 
recent infection or perhaps persisting viral antigen.
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Several workers have devoted much time and 
effort towards the development of CBV specific IgM 
assays, using the modern virological technique of 
enzyme linked immunosorbent assay (ELISA) and 
radioimmunoassays (RIA) (15, 16, 17). All have
detected nonspecific cross-reactions, some not only 
internally within the CBV group, but also externally 
with other enteroviruses. Attempts to apply some of 
these techniques in routine diagnostic testing are 
described in the following chapters.
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CHAPTER 3
The u antibody capture ELISA for the detection of 
Coxsackie B virus (CBV) specific IgM antibody.
I. INTRODUCTION.
Humoral immunity following viral infection is 
dependent on the production of IgG, IgM and IgA 
antibodies. IgG and IgM are found circulating in the 
blood stream and are the main classes of antibodies 
detected by viral serology. IgA is a secretory 
antibody found at the site of viral replication and is 
not normally used as a marker of viral infection.
Viral specific IgG antibody usually persists for life 
whereas antibody of the IgM type is short lived and 
characterises primary infection. It is possible that 
persistence or reactivation of virus in an active 
antigenic form may also be accompanied by a prolonged 
or recrudescent IgM antibody response. Thus tests for 
the detection of viral specific IgM offer the 
possibility of a rapid specific diagnosis on a single 
serum specimen sampled early after the onset of 
illness.
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The technique known as ELISA was pioneered by 
Engvall et__aJL. (1,2) and Van Weemen and Schuurs (3,4).
It depends on the linkage of soluble antigens or 
antibody to a solid phase without altering 
significantly their immunological specificity or 
reactivity. Then soluble antibody or antigen , 
conjugated with an enzyme such as horseradish
peroxidase or alkaline phosphatase, can be used for
/ -
detection with the enzyme activity being demonstrated
after the addition of chromogenic substrates.
Various techniques employing this
phenomenon have been described both for the detection
of viral antigens and antibody.
The technique described in this chapter was
developed by King et al. (5) for use in the evaluation
of the role of CBV in the aetiology of juvenile onset
diabetes mellitus.
The scientific basis of the test is an amalgam of the 
two classical solid phase immunoassays, namely, 
indirect u antibody capture and the sandwich technique, 
which is summarised in Figure.3.1.
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Figure 3.1
mtibody capture ELISA for the detection of CBV specific IgM.
V T \  
M L
I I FT I
Wells of the plate 
coated with sheep 
anti - human IgM 
(u chain specific).
Patient's serum is 
added; any IgM anti­
body present is 
captured on to the 
solid phase.
CBV single serotype is 
added. This will attach 
to any specific IgM 
antibody present.
Mouse anti - CBV 
antiserum is added. This 
will link to any CBV 
present.
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Figure 3.1 continued,
Goat-antij-mou se serum(IgG) 
conjugated to horseradish 
peroxidase is added; this 
will link to any mouse 
IgG present.
0 - phenylenediamine 2HC1 
+ HiOa. m  •
substrate is added. This • m « m
will form a yellow colour in 
presence ofthe horseradish
m m  m + m m  m m
peroxidase. The intensity of 
the colour produced is 
directly proportional to 
linked goat-anti-mouse IgG, hence to the 
mouse anti-CBV IgG absorbed to its 
specific antigen.
T
- =
IT" H 11
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Antihuman IgM u - chain specific, is coated onto 
the surface of microtitre wells. Patient's serum is 
added and any IgM present, regardless of specificity, 
will be captured by the anti - u antibody.
CBV is then added, and this will attach to any 
homologous CBV-specific IgM which has been captured 
onto the solid phase, making this a specific test for 
the virus. The presence of bound virus is detected 
using a mouse anti-CBV antiserum and a goat anti - 
mouse horseradish peroxidase conjugate in the 
classical patients serum-antigen-antiserum-antispecies 
serum sandwich. The intensity of the produced colour 
is therefore directly proportional to the amount of CBV 
specific IgM in the patient's serum.
II MATERIALS AND REAGENTS.
Microtitre plates.
These were ELISA grade flat bottomed polycarbonate 
microtitre plates (Dynatech Ltd.).
Coating antibody.
This was antihuman IgM (u chain specific), raised in 
sheep and affinity purified, and supplied in liquid 
form with 0.1% azide preservative, aliquoted and stored 
at -20°C. (Scottish Antibody Production Unit; SAPU.).
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CBV antigens.
CBV serotypes 1-5 complement fixing antigens with 
minimum CF titres of 1 in 8, as determined by 
chessboard titration were used. These were supplied as 
a frozen suspension of live virus grown in Vero cells 
(M.A. Bioproducts, Maryland, USA), and stored at -70°C
Control antigen.
The antigen was prepared from uninfected Vero cells in 
exactly the same way as the CBV antigens and also 
supplied by M.A. Bioproducts.
CBV antisera.
The positive control antisera to CBV types 1-5 were 
prepared for complement fixation tests (CFT) with 
minimum CFT titres of 1 in 8 as determined by 
chessboard titration.(M.A. Bioproducts). All sera were 
raised in mice. These were aliquoted and stored at - 
20°C.
Conjugate.
This was horseradish peroxidase-conjugated antimouse 
serum raised in goats and absorbed with human serum 
proteins (Sigma Ltd.). It was aliquoted and stored 
at -20°C
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Substrate.
This was crystaline O-phenylenediaminedihydrochloride 
(OPD),(Sigma Ltd.)* it was stored dess] cated at -20°C 
For use lOOmg was dissolved in 100ml of substrate 
buffer(see below) and 0.8ml of 10 vol H202 added before 
use. The substrate was always prepared immediately 
before use.
Acid.
IN H2S04 analar grade (BDH Ltd.) was employed for 
stopping development of the colour.
Buffer Solutions.
All chemicals used in the preparation of buffers were 
grcxd.Q-
of Analar^(BDH Ltd, Burntfield avenue, Thornliebank, 
Glasgow)
Coating buffer.
This was carbonate-bicarbonate buffer at pH 9.6. Its 
recipe was: 1.159g Na2CQ3, 2.93g of NaHC03 and 0. 2g of 
NaN3 dissolved in a total of 1000ml of deionised water. 
Its pH was then checked and adjusted to pH 9.6 with 
carbonate or bicarbonate if required. If the working 
pH varied by more than 0.4 units, fresh buffer was 
prepared. The prepared buffer was stored at room 
temperature for up to 14 days.
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Washing/serum buffer.
One tablet of phosphate buffered saline (Dulbecco's 
Solution A; Oxoid Ltd.) was dissolved in 100ml of 
deionised water and 0.1ml of Tween 20 (BDH Ltd.) added. 
The buffer was stored at room temperature for up to 14 
days.
Test buffer.
Washing buffer with added 25% lamb serum (Gibco Ltd.), 
was freshly prepared daily from stocks of washing 
buffer. The lamb serum was stored at -20°C.
Substrate buffer.
This was phosphate citrate buffer at pH 5.0, prepared 
to the following recipe: 24.3ml of 0.1M citric acid and 
25.7ml of 0.2M Na2HP04 were added to 50ml of deionised 
water, and this was stored at 4°C for up to 14 days.
Ill STANDARDISATION OF TEST REAGENTS.
Patients' sera and CBV antisera were used at fixed 
dilutions of 1 in 400 The conjugate was used at the 
manufacturer's recommended optimal working dilution, 
usually 1 in 1000. The coating antibody and CBV 
antigens were titrated against each other to determine 
their optimum working dilutions. Each new batch of 
antigen was standardised using the determined working 
dilutions of the other reagents.
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Coating antibody / CBV antigen titration.
(a) Serial doubling dilutions of coating antibody 
were prepared in coating buffer from 1/50 - 1/1600, and 
lOOul of each dilution was transferred into 4 columns 
of 12 wells of a microtitre plate (see Figure 3.2).
The plates were covered with a loose fitting lid and 
incubated in a humidity chamber at 4°C over night.
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Figure 3.2 
Layout of plates for coating antibody/ 
CBV antigen titration
COATING ANTIBODY DILUTIONS
|| 1/50 | 1/100 || 1/200 | 1/400 || 1/800 | 1/1600 ||
T
T
C
P P N N 
1/5
P P N N 
1/5
P P N N 
1/5
P P N N 
1/5
P P N N 
1/5
P P N N 
1/5
T
T
C
1/10 1/10 1/10 1/10 1/10 1/10
T
T
C
1/15 1/15 1/15 1/15 1/15 1/15
T
T
C
1/30 1/30 1/30 1/30 1/30 1/30
T = Test well 
C = Control well
Steps 1. Add coating antibody diluted 1/50 - 1/1600.
2. Add known positive and negative patients
serum at 1/400 to columns P(positive) and columns 
N(negative) respectivly.
3. Add CBV antigen to Test well rows and control antigen 
and control antigen to Control well rows at the 
dilutions shown.
4. Add homologous mouse anti-CBV serum at 1/400 to all 
wells
5. Add goat anti-mouse HRP conjugate at 1/1000 to all 
wells
6. Add substrate to all wells.
7. Stop the reaction after 10 - 20 mins and read plates.
The plates were then washed three times in washing 
buffer, as described below.
Washing procedure.
The microtitre plates were held upside down over a sink 
and the contents forcibly shaken out. All the wells 
were then filled with washing buffer and each plate 
allowed to soak for 60 seconds. This process was 
repeated three times. Following the third wash the 
plates were forcibly slapped on to absorbent paper 
towels to remove all excess liquid from the wells.
The plates were not allowed to dry out before the next 
set of reagents were sequentially added, as follows:
(b) A known negative and positive human serum 
(originally gifted by Professor Banatvala, St. Thomas' 
Hospital, London) were diluted 1/400 in serum buffer; 
100 ul of each serum was added to two columns of 12 
wells for each dilution of coating antibody.
The plates were incubated in a humidity chamber 
for 3 hours at 37°C, and then washed as before.
(c) CBV antigens and control antigens were diluted 
1/5, 1/10, 1/15 and 1/30 in test buffer, and 100 ul of 
each dilution of CBV antigen was added to 4 columns of
2 wells for each dilution of coating antibody, while 
100 ul of the appropriate dilution of control antigen 
was added to the third well of each column.
Thus each microtitre plate was divided into 8
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sections of 12 wells, each section representing one 
dilution of CBV antigen tested against one dilution of 
coating antibody using duplicate positive and negative 
human sera.
The plates were then incubated overnight at 4°C in 
a humidity chamber, and then washed as before. Next 
100 ul of a 1/400 dilution of the appropriate CBV 
antiserum in test buffer was added to all test and 
control wells. The plates were incubated in a 
humidity chamber at 37°C for 2 hours and washed.
Conjugate, at its working dilution of 1/1000 in 
test buffer , was added in 100 ul amounts to all the 
test and control wells. The plates were again 
incubated in a humidity chamber at 37°C for 3 hours, 
and then washed.
Substrate was prepared as above and 100 ul added 
to all the test and control wells, while 100 ul of 
substrate was also added to one row of eight wells of a 
fresh microtitre plate to be used as blanks for the 
plate reader. The plates were then incubated in the 
dark at room temperature for 15 minutes. The reaction 
was stopped by adding 100 ul of HC1 to all the wells, 
including the blanks.
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Plate readings.
Using a Titertek Multis^an MC Spectrophotometer on 
a dual wavelength programme the plates were read at A45Q 
using an interference filter of A64Q. The reading was 
presented on a scale between 0-2.000. The result for 
each serum was taken as the mean of the two CBV antigen 
readings minus the reading of the control well. 
Computation of the final results was done on a BBC 
micro computer interfaced with the Multisfean, the 
commercially purchased programme giving a printout in 
numerical sequence of readings on an Epsom FX-80 dot 
matrix printer. (Format BOB, Figures 3.3 and 3.4). 
Results.
Figure 3.5 illustrates results obtained when 
titrating coating antibody and CBV 5 antigen. The 
graph shows the absorbency values of each dilution of 
CBV 5 (positive serum means) plotted against the 
varying dilutions of coating antibody. The peak of 
each coincides with a coating antibody dilution of 
1/400. This dilution was thereafter used in the 
subsequent routine ELISA test.
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Figure 3.3.
Antihuman IgM/CBV 5 Titration.
Print out of results.
FORMAT BOB 12/05/86.
ANTIGEN
SAMPLE BLOCK AVERAGE No. OF STD DILUTION
NAME VALUE WELLS DEV
1 H1-H2 0.625 2 n<3
1C H3- - 0.007 1 n<3
2 G1-G2 0.614 2 n<3
2C G3- 0.008 1 n<3 1/5
3 F1-F2 0.009 2 n<3
3C F3-. 0.007 1 n<3
4 E1-E2 0.009 2 n<3 A
4C E3- ; 0.008 1 n<3 N-
T -
5 H4-H5 0.395 2 n<3 I
5C H6- 0.005 1 n<3
6 G4-G5 0.398 2 n<3 H
6C G6- 0.007 1 n<3 1/10 U
7 F4-F5 0.010 2 n<3 M
7C F6-_- 0.006 1 n<3 A
8 E4-E5 0.008 2 n<3 N
8C E6- 0.006 1 n<3
Icr
9 H7-H8 0.231 2 n<3 M
9C H9- , 0.008 1 n<3
10 G7-G8 0.237 2 n<3 1/
10C G9- 0.007 1 n<3 50
11 F7-F8 0.009 2 n<3 1/15
11C F9- _ 0.008 1 n<3
12 E7-E8 0.011 2 n<3
12C E9- 0.007 1 n<3
13 H10-H11 0.110 2 n<3
13C H12- 0.007 1 n<3
14 G10-G11 0.106 2 n<3
14C G12- 0. 008 1 n<3 1/30
15 F10-F11 0.008 2 n<3
15C F12- 0.009 1 n<3
16 E10-E11 0.008 2 n<3
16C El 2- . 0.008 1 n<3
17 D1-D2 0.698 2 n<3
17C D3-i 0. 010 1 n<3
18 C1-C2 0.664 2 n<3
18C C3- 0.007 1 n<3 1/5
19 B1-B2 0.011 2 n<3
19C B3-' J 0.009 1 n<3
20 A1-A2 0.011 2 n<3
20C A3- 0.006 1 n<3
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Figure 3.3 continued.
21 D4-D5 0.450 2 n<3
21C D6- 0.007 1 n<3
22 C4-C5 0.428 2 n<3
22C C6- 0.007 1 n<3
23 B4-B5 0.011 2 n<3
23C B6- 0.006 1 n<3
24 A4-A5 0.009 2 n<3
24C A6-. 0.006 1 n<3
25 D7-D8 0.292 2 n<3
25C D9- 0.008 1 n<3
26 C7-C8 0.260 2 n<3
26C C9- 0 .008 1 n<3
27 B7-B8 0.008 2 n<3
27C B9-1 0.008 1 n<3
28 A7-A8 0.008 2 n<3
28C A9-. 0.008 1 n<3
29 D10-D11 0.133 2 n<3
29C D12- 0.008 1 n<3
30 C10-C11 0.128 2 n<3
30C C12- 0.009 1 n<3
31 B10-B11 0.008 2 n<3
31C B12-.. . 0.007 1 n<3
32 A10-A11 0.008 2 n<3
32C A12- 0.006 1 n<3
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Figure 3.4.
Antihuman IgM/CBV 5 titration.
Antigen Antihuman IgM.
dilution . 1/50 1/100 1/200 1/400 1/800 1/1600
1/5 p 618 688 733 861 761 695
P 606 657 788 862 743 589
n 002 002 005 006 005 006
n 001 005 006 006 006 006
1/10 p 390 443 427 551 441 348
P 391 421 500 546 453 347
n 004 005 004 005 005 006
n 002 003 005 005 006 006
1/15 p 223 284 289 319 261 182
P 230 252 302 313 264 184
n 004 000 002 002 006 004
n 001 000 003 001 005 006
1/30 p 103 115 125 139 110 076
P 098 119 132 139 112 084
n 001 001 001 001 004 007
n 000 002 000 002 003 004
P = positive control serum.
n = negative control serum.
Mouse antiserum used at 1/400
Conjugate used at 1/1000
— ------------------________ _________________ . _ ___________  .____ __________ „ _______
All OP readings given in the following tables, 
graphs and figures other than those which are actual 
computer or reader printouts are expressed as units 
on a scale 0 - 2000.
Unit OP reading x 1000.
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Figure 3.5 
Anti human IgM/CBV 5
Positive control sera.
1000
800
600
400 BV5 1/10
200
BV5 1/30
10000100 100010
Antihuman IgM(LoglO)
CBV 5 1/30 
CBV 5 1/10
CBV 5 1/15 
CBV 5 1/5
Figure 3.6.
Antihuman igM(l/400)/CBV 5 titration
Absorbance values at 492nM.
1000
800
600
400
200
0 6 10 15 20 25 3530
Reciprocal CBV Antigen Dilutions
The. solid horizontal line* marks the optimal OD 
for this serum of 0.300 giving a CBV 5 antigen 
dilution of 1/17.
n  3
Using coating antibody at 1/400, Figure 3.6 
shows the absorbency values of the positive serum 
versus the different CBV 5 concentrations. The 
optimal absorbency value of this particular serum is 
0.300 +/- 20% (as predicted from repeat routine 
testing). Reading from the graph, a dilution of 
between 1/14 and 1/17 would give the desired result. 
Consequently a dilution of 1/15 was selected for use in 
the routine ELISA test.
Frequent testing of numerous batches of 
commercial antigens showed that most had an optimal 
using dilutions of 1/15, test dilution^.ower than this 
were not found. Because of this it was decided to use 
the commercial antigens at 1/15 without pretesting, 
saving approximately £100 per batch of 5 CBV antigens 
purchased. Only when positive and negative control 
sera gave inconsistent results were the CBV antigens 
re-titrated.
Coating antibody was much more variable, and 
consequently each batch was titrated against a single 
CBV antigen before use in the routine ELISA test.
74
2.PREPARATION OF IN-HOUSE CBV ANTIGENS.
Due to the high cost of commercial CBV antigens (a 
cost of £800 for 5ml each of CBV 1-5, plus 5ml of 
control antigen) it was decided that the preparation 
of in-house antigens should be attempted.
I Materials and reagents.
Cell cultures
Vero cells were grown in 175 cm2 plastic tissue culture 
flasks (NUNC), as described in Chapter 2.
PBS
This was Dulbecco's phosphate buffered saline solution 
A with 0.1% phenol red indicator (GIBCO Ltd).
Medium
Eagle's MEM with 5% lamb serum and 1% 
penicillin/streptomycin solution was employed. The 
antibiotic solution incorporated gave 10,000 iu 
penicillin / 10,000ug streptomycin per ml. (GIBCO Ltd). 
Salt solution
This was Dulbecco's solution B (Oxoid Ltd), which 
contained calcium and magnesium ions.
Seed virus
This was cell lysates of Coxsackie B virus types 1-5 
supplied as complement fixing antigens (M.A.
Bioproducts).
Footnote. ^Lamb serum was chosen as it was used in the 
i ELISA test as a blocking agent, thus its use here would 
reduce the risk of non-specific reactions in the ELISA 
test with in-house antigens. f
Preparation.
Confluent monolayers of Vero cells were washed three 
times with PBS and inoculated with 0.5ml of seed virus 
in 20ml of PBS (containing 1% salt solution). The 
virus was allowed to absorb onto the cells for 2 hours 
at 37°C. Control antigen was prepared in parallel 
using 20ml of PBS/1% salt solution only. The inocula 
were removed and replaced by 20ml of maintenance 
medium, and the flasks were reincubated at 37°C until 
complete (100%) cytopathic effect was observed (18-36 
hours). The flasks were then frozen to -20°C and 
thawed at room temperature three times. The resultant 
preparation was aliquoted and stored at -70°C.
Standardisation.
Antigens, prepared and stored as described above, were 
tested at varying dilutions against known positive and 
known negative human sera in duplicate. All other 
reagents were used at their optimal working dilutions. 
Incubation times , temperatures and washing procedures 
were all as previously described in this chapter.
One microtitre plate was sufficient for each 
antigen titration. The dilutions ranged from 1/2 - 
1/24 . The layout of a typical test (CBV 1 and CBV 4 
antigen titrations) is shown in Figure 3.7. The 
print-out obtained for the CBV 1 antigen in given in
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Figure 3.8. The final results were then transferred 
to worksheets (Figure 3.9).
The average OD value for the positive serum at 
each of the CBV antigen dilutions was then calculated 
and a graph of the OD values against CBV antigen 
dilutions plotted (Figure 3.10). The optimum CBV 
antigen concentration was taken as the highest dilution 
giving the expected OD value for the positive serum 
used in the test. Figure 3.10 shows the graphs 
obtained for CBV 1 batch RH 1/86 and CBV 4 batch RH 
1/86. The expected OD value for each serum was 0.500 
+ 20%, which gave working dilutions of 1/6 and 1/10 for 
CBV 1 RH 1/86 and CBV 4 RH 1/86 respectively.
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Figure 3.7 
Titration of In - House CBV Antigens.
H E D B
1/2 T
T
T
T
T
T
T T
T
1/12
1/4
T T T
T T 1/16
1/8
T T T T T T
T T T 1/20
10
1/10 11 
12
T T T T
T T T 1/24
P P N N 
1/400 
coating antibody
P P N N 
1/400 
coating antibody
T = CBV Antigen 
C = Control Antigen 
P = Positive serum 
N = Negative serum
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Figure 3.8
Titration of In-House CBV Antigens 
Print out of results.
FORMAT BOB 15/09/86.
SAMPLE SAMPLE BLOCK AVERAGE No. OF STD CBV
NUMBER NAME VALUE WELLS DEV ANTIGEN
DILNS
IT 1 H1-H2 0.677 2 n<3 P
2C 1C H3-1 _ 0.009 1 n<3 P
3T 2 G1-G2 0.656 2 n<3 P
4C 2C G3-. , 0.011 1 n<3 P 1/2
5T 3 F1-F2 0.018 2 n<3 N
6C 3C F3-L i 0.008 1 n<3 N
7T 4 E1-E2 0.017 2 n<3 N
8C 4C E3-- : 0.007 1 n<3 N
9T 5 H4-H5 0.562 2 n<3 P
10C 5C H6-: 0.002 1 n<3 P
11T 6 G4-G5 0.522 2 n<3 P
12C 6C G 6-v 0.000 1 n<3 P 1/4
13T 7 F4-F5 0.013 2 n<3 N
14C 7C F6-1 : 0.000 1 n<3 N
15T 8 E4-E5 0.012 2 n<3 N
16C 8C E6- 0.001 1 n<3 N
17T 9 H7-H8 0.389 2 n<3 P
18C 9C H9-.' 0.011 1 n<3 P
19T 10 G7-G8 0. 382 2 n<3 P
20C 10C G9- 0.010 1 n<3 P 1/8
21T 11 F7-F8 0.013 2 n<3 N
22C 11C F9-: 0.009 1 n<3 N
23T 12 E7-E8 0.011 2 n<3 N
24C 12C E9-. > 0.009 1 n<3 N
25T 13 H10-H11 0.312 2 n<3 P
26C 13C H12- 0.016 1 n<3 P
27T 14 G10—Gil 0.318 2 n<3 P
28C 14C G12- 0.013 1 n<3 P 1/10
29T 15 F10-F11 0.013 2 n<3 N
30C 15C F12- 0.014 1 n<3 N
31T 16 E10-E11 0.010 2 n<3 N
32C 16C E12- 0.011 1 n<3 N
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Fig 3.8 continued.
33T 17 D1-D2 0.344 2 n<3 P
34C 17C D3- 0.008 1 n<3 P
35T 18 C1-C2 0.346 2 n<3 P
36C 18C C3- 0.011 1 n<3 P 1/12
37T 19 B1-B2 0.014 2 n<3 N
38C 19C B3- , 0.010 1 n<3 N
39T 20 A1-A2 0.012 2 n<3 N
40C 20C A3- _ 0.009 1 n<3 N
41T 21 D4-D5 0.227 2 n<3 P
42C 21C D6- 0.002 1 n<3 P
43T 22 C4-C5 0.224 2 n<3 P
44C 22C C6- 0.002 1 n<3 P 1/16
45T 23 B4-B5 0.011 2 n<3 N
46C 23C B6- 0.002 1 n<3 N
47T 24 A4-A5 0.011 2 n<3 N
48C 24C A6- 0.001 1 n<3 N
49T 25 D7-D8 0.207 2 n<3 P
50C 25C D9-. 0.009 1 n<3 P
51T 26 C7-C8 0.202 2 n<3 P
52C 26C C9- 0.010 1 n<3 P 1/20
53T 27 B7-B8 0.012 2 n<3 N
54C 27C B9-: 0.009 1 n<3 N
55T 28 A7-A8 0.011 2 n<3 N
56C 28C A9- 0.008 1 n<3 N
57T 29 D10-D11 0.184 2 n<3 P
58C 29C D12- 0.010 1 n<3 P
59T 30 C10-C11 0.182 2 n<3 P
60C 30C C12- 0.010 1 n<3 P 1/24
61T 31 B10-B11 0.011 2 n<3 N
62C 31C B12“ 0.011 1 n<3 N
63T 32 A10-A11 0.010 2 n<3 N
64C 32C A12- 0.011 1 n<3 N
T = CVB Antigen 
C = Control antigen 
P = Positive Serum 
N = Negative Serum
FORMAT BOB = Self programmed Format on BBC microcomputer.
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Figure 3.9. 
Titration of In-House CBV Antigens 
RH 1/86 CBV1 and CBV4 Titration.
SERUM ANTIGEN ANTIGEN
Antigen B1 B4
Dilution
P 668 829
P 1/2 645 853
N 010 018 P=POSITIVE
N 010 017 SERUM
P 560 788 N=NEGATIVE
P 1/4 522 759 SERUM
N 013 015
N 011 015
Antihuman
P 378 568 IgM used at
P 1/8 372 552 1/400.
N 004 014
N 002 014
Mouse anti
P 296 504 CBV serum at
P 1/10 305 490 1/400
N -001 013
N 001 014
Conjugate
P 336 430 (SIGMA)
P 1/12 335 427 at 1/1000.
N 004 014
N 003 013
P 225 346
P 1/16 222 354
N 009 013
N 010 014
P 198 264
P 1/20 192 277
N 003 011
N 003 012
P 174 239
P 1/24 172 234
N 000 011
N -001 011
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Figure 3.10
T itra tio n  of In -h o u s e  CBV antigens  
RH 1/86 CBV 1 and RH 1/86 CBV 4
A 1000
b 
s 
o 
r 
b 
a 
n 
c 
e
800
600
400
v
a
1
u
e
s
200
2520
ANTIGEN DILUTIONS
RH 1/86 CBV 4 ~ R h  1/86 CBV 1
Foot Note
The solid horizontal lines* mark the optimal OD 
readings for the positive sera used; giving 
dilutions of 1/5 for CBV 1 and 1/10 for CBV 4.
Evaluation of in-house CBV antigens.
A panel of 16 sera known to give a reasonable 
array of positive(+ to +++), weak positive(+) and 
negative(-) results with commercial antigens in routine 
testing was prepared (Fig 3.11, A and B). Each of 
these sera was tested in duplicate against the in-house 
CBV antigens, prepared in this laboratory, used at 
their optimal dilutions. The results obtained were 
then compared with those obtained with commercial 
antigens, because a good correlation (100%) with the 
positive and negative sera with a variety of antigens 
was essential. Weak positive reactions (+) were less 
reliable and an 80% or better correlation was 
acceptable. In-house CBV antigens meeting these 
requirements were aliquoted in volumes sufficient for a 
single batch of tests and stored at -70°C until 
required.
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Figure 3.11A
Standardisation of In - House antigens.
Panel of Quality Control sera.
Expected
B1 result, B1 reading, B1 result,
I.D. Commercial In - house In - house
No. Antigen Antigen Antigen
1 -  001
2 - Oil
3 - 002
4 - 000
5 - 003
6 + 031 +
7 +++ 282 ++
8 - 003
9 ++ 233 ++
10 + 057 +
11 - 003
12 +/- 018 Eq
13 - 002
14 - 003
15 - 002
16 - 003
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Figure 3.11A (continued)
Standardisation of In - House antigens.
Panel of Quality Control sera.
I. D.
No.
1
2
3
4
5
6
7
8
9
10 
11 
12
13
14
15
16
Expected 
B1 result, 
Commercial 
Antigen
+
+++
++
+
+/-
B1 reading, 
In - house 
Antigen 
001 
009 
003 
001 
002 
033 
284 
002 
233 
049 
000 
019 
002
003 
000
004
B1 result, 
In - house 
Antigen
+
++
++
+
Eq
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Figure 3.1IB.
Standardisation of In - House antigens.
Panel of Quality Control sera.
Expected
B4 result, B4 reading, B4 re:
I.D. Commercial In - house In - ]
No. Antigen Antigen Ant
1 - 009 -
2 - 015 -
3 + 049 +
4 - 010 -
5 - 007 -
6 +++ 615 +++
7 ++ 375 H—h
8 - 018 Eq
9 + 168 ++
10 + 071 +
11 - 008 -
12 +/- 024 +/-
13 - 007 -
14 - 005 -
15 - 009 -
16 _ 004 -
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Figure 3.11B (continued)
Standardisation of In - House antigens.
Panel of Quality Control sera.
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3. THE SELECTION AND USE OF CONTROL SERA.
The selection of good control human serum for 
ELISA tests is critical if the test system is to be 
successful. Three known positive sera (one high, one 
medium and one low) and five negative control sera were 
titrated against each CBV antigen tested. Earlier 
experiments had shown that one set of control sera per 
batch of tests , titrated in a separate plate, was 
inadequate because of between-plate variation, and 
variations in reading times. Total confidence in the 
results was only gained by including controls on each 
plate(ie; within-plate controls).
Initially CBV IgM positive control sera were 
obtained from Professor Banatvala of St.Thomas'
Hospital London. These were used as controls in ELISA 
tests done with selected sera with known rising titres 
(>4 fold) or high (>512) titres provided by the 
conventional neutralisation tests. From the results, 
sera giving a variety of positive responses to one 
(monotypic) or more (heterotypic) CBV serotypes were 
selected for use as control sera. Such sera were:
1. those giving a monotypic response and absorbency 
values of between 0.300 - 0.600 to each CBV serotype (B 
1 - 5 ) =  high positive control: 2. a serum that gave
absorbency values of between 0.070 - 0.150 to all 5 CBV 
serotypes (heterotypic) = medium positive control:
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3. one serum for each CBV serotype that gave absorbency 
values of between 0.030 - 0.050 (monotypic) = low 
positive control. Each positive control serum 
selected was retested in duplicate against CBV 1-5 to 
confirm the reproducibility of results before being 
used in the test proper. All the positive control 
sera were stored at 4°C for up to 4 weeks.
Sera from the above tests which gave absorbency 
values of between 0.007 - 0.015 against all 5 CBV 
serotypes were then pooled. This negative control 
pooled sera was first retested in quintuplicate against 
all 5 CBV serotypes to ensure that it was consistently 
negative, and then aliquoted in 0.2ml volumes and 
stored at -20°C.
A continuing supply of positive control sera was 
obtained by careful selection from the routine tests on 
patients7 sera. This avoided undesirable variations 
in levels of IgM which might result from long - term 
storage of any selected sera. Control sera in use
at any one time were used in all titrations of CBV 
antigens and other reagents.
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4 THE DEVELOPED ROUTINE TEST METHOD.
Day 1.
Coating of plates. Anti human IgM was diluted to the 
test dilution in coating buffer, and lOOul was added to 
all wells of 5 microtitre plates. This allowed 24 
test sera and 8 control sera to be tested against all 5 
CBV serotypes, employing one antigen per plate. The 
plates were incubated overnight at 4°C in a humidity 
chamber. Plates may be left at this stage for up to 
72 hours before further use without adversely affecting 
the final results of the test.
Day 2.
Worksheets were prepared with lists of the 
control and patients sera to be tested . A 1/400 
dilution of each test and control serum was made in 
washing buffer (0.025ml sera + 10ml buffer). Coated 
plates from day 1 were washed three times in washing 
buffer and lOOul of each diluted serum was added to a 
column of 3 wells on each plate (see Figure.3.12).
The plates were then covered and incubated at 37°C for 
three hours.
CBV and control antigens were diluted to test 
dilutions in test buffer. The plates were washed (as 
above) and 100 ul of a CBV antigen was added to the 
first 2 of the 3 serum wells on its appropriate plate
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and lOOul of control antigen was added to the third 
well of each column on all 5 plates. The plates were 
then incubated at 4°C overnight in a humidity chamber. 
Day 3.
CBV antiserum dilutions were prepared in test 
buffer. The plates were washed (as above) and lOOul of 
antiserum was added to all the wells of the appropriate 
plates (see Figure 3.11C). The plates were then 
incubated for 2 hours at 37°C in a humidity chamber.
Conjugate was next diluted to its working dilution 
in test buffer. The plates were washed (as above) and 
lOOul of diluted conjugate was added to every well.
The plates were then incubated at 37°C for 3 hours in a 
humidity chamber.
At the end of this incubation period the substrate 
was prepared and stored in the dark at room temperature 
until used (for a maximum period of 10 - 15 minutes). 
The plates were then washed (as above) and lOOul of 
substrate was added to every well together with a 
column of 8 wells in a new blank plate. The plates 
were incubated at room temperature in the dark for 15 
minutes. All reaction was stopped by then adding lOOul 
of IN H2S04 to every well, including those in the new 
blank plate.
The plate reader and computer were next prepared 
for use. The reader was zeroed using the blank plate
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before the readings of the test plates were made. The 
raw data were processed using the computer programme 
and the final results were transferred to the 
worksheets.
Further batches of patients sera were readily 
tested on a rotational basis e.g., start Day 2 - finish 
Day 4; start Day 3 - finish Day 5? coat Day 5(for 72 
hours) - finish Day 2.
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Figure 3.12. 
Routine test method.
PI P2 P3 N N N N N T T T T T T T T S s s S s s s s
PI P2 P3 N N N N N T T T T T T T T S s s S s s s s
PI P2 P3 N N N N N C C C C C C C C S s s s s s s s
XI X2 X3 X4 XEi X6i X7 X8 T T T T T T T T S s s s s s s s
1 2 3 4 5 6 7 8 T T T T T T T T s s s s s s s s
1 2 3 4 5 6 7 8 C C C C C C C C s s s s s s s s
X9 10 11 12 13 14 15 16 T T T T T T T T s s s s s s s s
X9 10 11 12 13 14 15 16 T T T T T T T T s s s s s s s s
X9 10 11 12 13 14 15 16 C C C C C C C C s s s s s s s s
17 18 19 20 21 22 23 24 T T T T T T T T s s s s s s s s
17 18 19 20 21 22 23 24 T T T T T T T T s s s s s s s s
17 18 19 20 21 22 23 24 C C C C C C C C s s s s s s s s
A B c
P = Positive control(1 - 3)sera. T = CBV antigen(1 - 5)
N = Negative control sera. C = Control antigen.
X = Patients sera (1 - 24) S = Coxsackie B antiserum.
(Homologous; one per plate)
A = patients serum added to plate.
B = Coxsackie B and control antigen added to plate.
C = mouse - anti - Coxsackie B virus serum added to plate.
Note for figure 3.12. One plate was used for each virus 
serotype CBV1 - 5. Positive and negative control sera were 
included in every plate, and five plates were required to test 
24 patients sera against all 5 viruses.
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Determination of results
The mean reading of the 5 negative control 
sera plus 3 standard deviations was used as a basis for 
determining a cut off value. A minimum cut-off of 0.020 
was invariably set.
Sera giving a reading lower than this were considered 
negative, while sera with a reading higher than the 
cut-off but less than two times this value were 
regarded as weak (+) positive and were re-tested to 
ensure reproducibility. Those sera giving a value 
greater than two times the cut-off were regarded as 
positive and were further graded from 1+ to 4+ 
depending on their test absorbency value, according to 
the following scale :-
1+ = 0.040 to 0.100
2+ = 0.101 to 0.500
3+ = 0.501 to 1.000
4+ = 1.001 to 2.000
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Discussion.
The detection of viral specific IgM 
antibody by the ELISA technique is gradually replacing 
the more cumbersome haemagglutination inhibition, 
complement fixation and neutralisation tests as the
standard technique of coxsackie B diagnostic viral serology.
The Coxsackie B IgM ELISA test described in this
chapter has the potential for replacing the current 
neutralisation test, and the test protocol may also 
prove similarly useful in investigating the role of 
other enteroviruses in other disease syndromes.
The test described here can readily be used for 
testing large numbers of patients' sera and has the 
advantage over neutralisation tests in that (a) a 
positive result represents a recent or an active 
infection, (b) only one serum sample per patient needs 
to be tested when obtained at the correct time in the 
illness, (c) results can be available within 48 hours 
of receipt of the sample at the test laboratory.
The high cost of the ELISA reagents needs to be 
weighed against the more labour intensive 
neutralisation tests. Further, ELISA tests offer speedy 
and significant results. The cost of the tests can be 
reduced dramatically by preparing "in-house" antigens, 
since the relatively crude preparations described in 
this chapter have proved both useable and reliable.
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Further purification of the antigens, involving high 
speed clarification and sedimentation followed by 
fractionation on sucrose and caesium chloride gradients 
have shown no significant advantage over the described 
unpurified in-house antigens. Further, the time and 
cost of reagents used to purify antigens has tended to 
cancel out any financial advantage offered over 
commercial preparations.
Freeze-dried antigen preparations, supplied by 
many commercial firms for use in the Coxsackie B virus 
complement fixation test, were found to be unsuitable 
for the ELISA test since they failed to provide 
positive test results when they were titrated against 
positive sera.
The application of this CBV IgM ELISA for the 
routine diagnosis of Coxsackie B infections is 
described in detail in chapter 4.
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CHAPTER 4
Use of the u - antibody capture ELISA in the routine
diagnosis of CBV infections.
I. Introduction.
Coxsackie B viruses (CBV) are normally 
endemic in the United Kingdom. They are associated 
with a wide spectrum of illness including aseptic 
meningitis, Bornholm disease, andfftyopericarditis. 
Isolation of virus from cases other than aseptic 
meningitis and Bornholm disease has generally been 
unsuccessful, and the identification of a possible 
viral cause has depended upon serological testing. 
Neutralisation tests (NT), and, to a lesser extent, 
complement fixation tests (CFT) have been the two main 
techniques used for the serological diagnosis of CBV 
infections. The more recent development of an 
enzyme-linked immunosorbent assay (ELISA) technique for 
the detection of CBV specific IgM (1) has added a new 
impetus to the serological investigation of CBV 
infections. I have evaluated this newly developed 
technique as it would apply to the daily routine of a 
serology laboratory and used it for the serological 
diagnosis of patients with cardiac and other illnesses
98
of suspected CBV aetiology.
II Materials and methods.
Patients studied. Most of these patients were from 
the West of Scotland, with others from East Scotland 
and occasionally from England. The clinical 
classification of patients was based entirely on 
information provided by hospital clinicians and general 
practitioners on requested-information cards 
accompanying specimens to the laboratory. Single 
convalescent sera were most commonly submitted for CBV 
investigations, the majority being from adults in the 
25-55 year age group. Follow-up serum samples were 
requested from certain patients in order to monitor the 
duration of CBV IgM antibody. Sera from controls were 
obtained from apparently healthy adults in the West of 
Scotland, sampled over the same period of time.
ELISA tests. The u-antibody capture technique 
described in chapter 3 was used. Plates were coated 
with sheep anti-human IgM (u-chain specific), and each 
serum tested at a dilution of 1/400 in duplicate 
against viral antigens CBV 1-5 and in parallel with 
control antigen. Three positive control sera (high, 
medium and low) and five negative control sera were 
included for each CBV antigen. The result for each 
serum was taken as the mean absorbence value of the two
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test wells minus the absorbence of the control antigen 
well. The cut-off point was taken as the negative 
serum control mean plus three standard deviations.
Sera giving a reading higher than this, but below a 
value of 2 times the cut off were regarded as weak 
positive (+); sera with readings of >2 times the cut 
off were regarded as positive and graded 1+ to 4+ (see 
page 96).
Neutralisation tests. Initially sera were tested by 
neutralisation test (NT). The microtitre 
neutralisation test described in chapter 2 was then 
used. The end points of the serum titrations were 
determined by microscopic examination for cytopathic 
effect rather than by colour change. Static titres of 
^512 or a four fold rise or fall in titre were regarded 
as indicative of recent CBV infection while titres of 
256 were only suggestive of this. Both positive and 
negative sera were selected for CBV IgM estimations.
In later test series sera were first screened by ELISA 
and only positives were tested by NT.
III. Results.
During 1984, before use of the CBV IgM ELISA 
test system, 1430 patients and a control group of 87 
healthy adults were tested by conventional NT. The 
results (Table 4.1) reveal that the % positives (titres 
^256) in each clinical category was higher than those
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recorded for equivalent disease categories studied 
during 1983 (2).
Table. 4.1.
Results of CBV Neutralisation Tests 
on 1430 Patients and 87 controls Tested in 1984.
CBV antibody titres 
To*Tal
Clinical Number of % % %
category patients tested >512 256 >256
Myopericarditis 352 33 22 55
Chest pain 374 23 19 42
M.E.* 210 35 15 50
Myalgia/Bornholm 164 24 15 39
Miscellaneous** 330 22 20 42
Total 1430 27 18 46
Healthy control
adults 87 5 12 17
* M.E. = Myalgic Encephalomyelitis
** Includes neurological illness, fatigue, muscle 
aches, etc. for whom CBV tests were specifically 
requested by clinicians.
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This increase i in positives reflected not only a 
better selection of patients by clinicians but also 
more strict criteria applied when selecting for 
testing. There was no significant increase in 
circulating CBVs, and the controls showed no 
significant change in antibody status (5% with titres 
of >512, 12% with titres of 256) compared with control 
groups studied during the last 10 years (2,3,4).
Sera with NT titres of >256 and titres of <128, 
selected from routine CBV NT were studied for the 
presence of CBV IgM by ELISA. These included patients 
in various clinical categories presenting with acute 
and chronic illnesses. A total of 273 sera were 
tested by ELISA; 122 were found to be CBV IgM positive, 
of which 101 (83%) were also positive (£256) by NT.
Only 8% of these were CBV IgM positive without 
confirmatory NT results (Table 4.2). On the basis of 
these results, a regimen was adopted of first screening 
sera for CBV 1-5 specific IgM by ELISA and then 
testing by NT only those which were found to be 
positive.
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Table 4.2.
Comparison of results on 273 sera from 
patients with suspected CBV infections 
tested in 1984.
NT positive NT negative Total
2 -is rk ) (<; /2 j s )
CBV IgM positive 101(37%) 21(8%) 122(45%)
CBV IgM negative 94(34%) 57(21%) 151(55%)
Total 195(71%) 78(29%) 273(100%)
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Between January and August 1985, 760 patients with 
suspected CBV infections were studied. The results 
are shown in Table 4.3. The percentage positive for 
each clinical category was similar to those listed in 
Table 4.1 when NT titres of ^512, indicative of recent 
infection, were compered.
Sera from 304 healthy adults in the West of 
Scotland were tested by ELISA at the same time, of 
which 132 (43%) were male and 173 (57%) female, with 
206 (68%) aged 20-49 years, and were similar inage and 
sex to the various disease groups. Only 26 (9%) of 
this control group were positive.
Details of the combined ELISA and NT findings in 
the 191 patients and 26 controls found positive in the 
CBV IgM screen are listed in Table 4.4. A strong 
correlation between positive CBV IgM and high NT titres 
was seen in the myopericarditis, chest pain, and 
myalgia/Bornholm categories (65 (90%), 40 (91%) and 11 
(92%) respectively) These illnesses are now 
recognised as having a CBV aetiology. The 
corresponding figure for the group with myalgic 
encephalomyelitis (ME) was 30 (83%). These results were 
compared with the control group, where only 2 (8%) of 
the CBV IgM positive sera were also NT positive.
A matching monotypic or heterotypic response by 
both test systems occurred in approximately 60-66% of
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all disease categories studied, with the exception of 
the miscellaneous group, which included illnesses less 
likely to have a CBV aetiology.
Cross-reactions between this CBV IgM ELISA test 
and other enterovirus infections were also 
investigated. The results of these tests are shown in 
Table 4.5.
Table 4.6 lists the variety of responses observed 
by CBV ELISA and by NT, and includes examples of the 
interpretation of results commonly found when using 
this diagnostic regimen.
Sequential sera were available for study from 52 
patients with acute or chronic illnesses. The 
duration of CBV IgM detection varied from 1 to 2 months 
in Bornholm disease, 3-6 months in myo/pericarditis 
(with recovery) and at least 1 year in some patients 
with relapsing ME.
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Table 4.3.
CBV IgM results in 760 patients 
and 304 controls tested in 1985.
Clinical Number of Number of CBV
category patients tested IgM positives(%)
Myopericarditis 220 72(33%)
Chest pain 198 44(22%)
M.E.* 118 36(31%)
Myalgia/Bornholm 62 12(19%)
Miscellaneous** 162 27(17%)
Total 760 191(25%)
Healthy control
adults 304 26(9%)
* M.E. = Myalgic Encephalomyelitis.
** Includes neurological illness, fatigue, muscle 
pain etc, for when CBV tests were specifically 
requested by clinicians.
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Table 4.4.
Correlation of CBV IgM positive 
and Neutralisation test results 
on 191 Patients and 26 Controls. 
Clinical categories.
Myo C/P M.E. My/B Misc Ctr
No. of Patientsp 72 44 36 12 27 26
IgM Pos/Neut Pos* 90% 91% 83% 92% 78% 8%
Matching monotypic
IgM and NT. 31% 27% 33% 33% 19% 0%
Matching heterotypic
Igffl and NT © 31% 32% 33% 33% 26% 0%
IgM positive
non matching NT. 28% 32% 17% 2§% 33% 8%
IgM positive
NT negative 0 10% 9% 17% 8% 22% 92%
Myo = Myopericarditis. M.E = Myalgic Encephalomyelitis 
C/P = Chest pain. My/B = Myalgia/Bornholm.
Misc = Miscellaneous. Includes neurological illness, 
fatigue, muscle aches and pains etc. Where CBV tests 
had been specifically requested by clinicians.
Ctr. = Controls. Health adult sera.
* NT positive = titres >256.
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Table 4.5.
CBV IgM ELISA CROSS REACTIONS.
Test serum No of Sera. CBV IgM Pos
HAV IgM Positive 14 14
Echovirus (CSF isolate) 12 12
Poliovirus NT >512/R T 5 0
HAV IgM Pos
CBV IgM positive 60 0
HAV = Hepatitis A virus.
A unique one-way cross with Hepatitis A virus 
(HAV; Enterovirus 72) IgM positive sera (Abbott 
Laboratories HAVAB-M test) was demonstrated. Of 14 
HAV IgM positive sera all gave CBV IgM positive 
reactions in this ELISA test. In contrast, of 60 
randomly selected CBV IgM positive sera from this 
study, none was found to be positive in the HAVAB-M 
test system. Heterotypic responses in the ELISA test 
were observed in all of the patients with proven 
systemic Coxsackie A or echovirus infections. No 
cross - reacting responses were observed in the 5 cases 
of poliovirus infection investigated.
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Table 4.6
CBV IgM and NT Responses Observed and Interpretation of 
the Results.
Patient Interval CBV IgM and Comments
After Neutralising Antibody titres(NT)
Onset B1 B2 B3 B4 B5
1. W.H. 36M 6 dy Rising B2 IgM and NT
Joint pains <64 <64 <64 <64 <64 indicate current
myalgia. 30 dy - ++ infection B2/B4
<64 256 <64 128 <64 cross reactions
are not uncommon
5 dy - - - - -  Rising B1,B3,& B5 NT 
<64 <64 <64 256 <64 IgM indicate current
15 dy • + -  + - +  infection; B4 NT
>.1024 <64 512 512 >.1024 suggests infection
earlier in life.
3. J.M. 59M 8 dy ++ - - + - Falling B1 IgM & NT
Muscle >.1024 <64 <64 256 <64 indicate infection
bone 22 dy - - - - in past weeks; note
aches 512 <64 <64 256 <64 cross reaction with B4
2. S.R. 37F 
Chest 
and arm 
pain.
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Table 4.6 continued
Patient Interval CBV IgM and Comments
After Neutralising Antibody titres (NT)
Onset B1 B2 B3 B4 B5
4. H.M. 37M ? dy + - - - - Static B1 IgM & NT
Pericarditis 256 64 <64 512 128 indicates recent
31 dy + - - - - infection.Note B4 &
256 64 <64 512 128 B5 anamnestic NT
responses.
5. A.S. 38M 2 dy - - - - - Slow rise in B5 (with
Myalgia, <64 <64 <64 64 <64 anamnestic B2)IgM but
chest pain. 12 dy - - - - - negative NT response
<64 <64 <64 64 <64 indicates current
34 dy - ± - - enterovirus infection
<64 <64 <64 64 <64 4th serum requested
to detechpossible late Bb NT rise.
6. S.M. 15F 7 wk - - - - - Negative IgM but high
Pericarditis. <64 512 <64 128 <64 static B2 NT; no
4 mo - - - - - evidence of recent
<64 512 <64 128 <64 enterovirus infection
11C)
Table 4.6 continued.
Patient Interval CBV IgM and Comments
After Neutralising Antibody titres(NT)
Onset B1 B2 B3 B4 B5
7. S.T. 40M 12 dy - + - + -
Persistent <64 <64 <64 512 <64 Persisting B4 IgM &
fatigue for 20 dy - ± - + - NT; ? persisting B4
4.5 months <64 <64 <64 512 <64 over this 5 month
11 wk - - - + - period.
<64 <64 <64 512 <64
5 mo - ± - + -
<64 <64 <64 512 <64
8. A.M. 51M 13 dy - - - - - Negative IgtJ but
myocarditis. 1024 512 <64 256 <64 rising B5 NT. ? No
23 dy - - - - - Igm response or
512 512 <64 256 512 present only at low 
(<1/400) levels.
9. K.E. 32F ? - - - + - B4 IgM & NT indicate
Asymptomatic <64 <64 <64 512 <64 recent infection; ?
but delivered related to baby's
baby who died cardiomyopathy. ( No
with cardiomyopathy. serum from baby).
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Table 4.6 continued.
Patient Interval CBV IgM and Comments
After Neutralising Antibody titres(NT)
Onset B1 B2 B3 B4 B5
10. E.R. 29F 8 dy + ++ + + Heterotypic IgM and
Pericarditis. 512 kl024 256 128 >.1024 matching high NT
response indicate recent CBV infection.
11. J.P. 32F 10 mo + + + + + Heterotypic IgM &
Myalgic <64 >.1024 256 <64 128 matching high B2 NT;
Encephalomyelitis. since acute serum was
not available interpretation 
is difficult but IgM/NT 
evidence suggests recent CBV infection.
12. C.L. 15F 4 dy + ++ - - ++ Heterotypic IgM with
Aseptic <64 <64 <64 64 64 negative NT indicates
meningitis. recent enterovirus
infection.
IV. Discussion.
Until recently, the only practical 
quantitative assessment of CBV antibodies was by (NT).
This test is labour intensive, and the interpretation 
of static high titres in the individual patient difficult.
Although quantitation of antibodies by ELISA requires detailed evaluation,—
. _ by introducing the u-antibody capture CBV-
specific IgM ELISA technique, it was hoped to provide a 
rapid, reliable and more precise serological diagnosis.
To evaluate this ELISA technique for the routine 
diagnostic laboratory the test was performed on 273 
sera selected from routine NT runs, and both NT 
positive and negative sera were included in the tests.
Eighty three percent of those sera positive by CBV IgM 
tests were also NT positive, and such results were 
considered to indicate recent CBV infection. Only 8% 
of the selected sera were CBV IgM positive but NT 
negative, thereby suggesting a recent infection by 
other non-CBV members of the enterovirus group. On 
the basis of these observations, I introduced a CBV 
serological diagnostic regimen of screening patients 
for CBV 1-5 specific IgM by ELISA. Only those 
positive in this assay had a confirmatory CBV 1-5 NT 
done on them, therebymaking a more rapid diagnosis 
possible. Within 3 days of receipt of a serum sample 
one of two possible reports could be issued: (1) the
serum is CBV IgM positive, indicating a current/recent
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enterovirus infection. The NT results will follow;
(2) the serum is CBV IgM negative, indicating no 
evidence of a recent enterovirus infection at the time 
this sample was taken.
Between January and August 1985, 760 patients with 
various illnesses of suspected CBV origin were tested. 
Most were adults in the 25-55 year age group. Thirty 
three percent of those with suspected myopericarditis 
were found to be CBV IgM positive, which is almost 
certainly an underestimate due to the inclusion of 
patients with less well defined clinical diagnosis (5). 
Since the association of CBV infections with 
myopericarditis is well recognised, this figure 
provided a positive control against which to assess 
serological results from other clinical categories.
A negative control figure was obtained by testing sera 
from 304 healthy adults sampled over the same time 
scale, of which only 26 (9%) of these were CBV XgM 
positive.
Previous studies in an outbreak of ME (6) 
suggested that the CBV group played an important role 
in this debilitating illness. This was confirmed 
here, with 36 (31%) of 118 patients with suspected ME 
recorded as positives in the CBV IgM test. The 
percentage positive in the other disease categories 
wdjfr-" lower, possibly reflecting less well defined
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clinical diagnoses. Nevertheless, the positives were 
still App.v^ CA(v!bV.\j  ^ higher than those in the negative 
control group.
The CBV IgM ELISA results obtained here show the 
range of both monotypic and heterotypic responses 
reported by others (1,7). Monotypic responses are 
most common in children under seven years of age (8). 
Although the type of illness investigated in this study 
involved mainly adults, matching monotypic ELISA and NT 
results were not uncommon, being observed in 
approximately one third of all cases excluding the 
miscellaneous group. Matching heterotypic responses 
in both tests were also seen in one third of those same 
categories. Only 8-10% CBV IgM positive sera were 
negative by NT in the myalgia / Bornholm, chest pain, 
and myopericarditis groups, implying recent infection 
with other enteroviruses. The corresponding figure 
for the healthy adult group was 92%, only 2 of the 26 
ELISA positive sera having elevated but non-matching NT 
antibody responses.
Cross reactions of this CBV IgM ELISA test with 
other members of the enterovirus group have been 
documented by various workers (1,7). The studies 
described here confirmed the unique one-way cross 
between this test and the hepatitis A virus (HAV) IgM. 
CBV IgM responses were also observed in patients with
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systemic Coxsackie A and echovirus infections, but not 
in the few poliovirus infections tested. Despite the 
disadvantages of such cross reactions, they appear to 
offer a scant problem in routine testing. Most of the 
patients were in the older age groups, where HAV 
infections are less common, while the categories of 
illnesses which were studied had a greater probability 
of being CBV-related than other-virus-related.
The duration of the detectable CBV IgM in sera was 
varied. In acute illnesses with rapid recovery, for 
example, in Bornholm disease, CBV IgM levels fell 
within 1-2 months; in the myopericarditis group the 
levels fell after 3-6 months. On the other hand 
persistent CBV IgM levels were detected for more than 
one year in some patients with myalgic 
encephalomyelitis.
Detection of monotypic CBV IgM with matching high 
monotypic NT response was regarded as indicating a 
recent primary infection with that CBV serotype while 
heterotypic but matching positive ELISA and NT results 
suggested a recent infection with an unspecified member 
of the CBV group. Interpretation of heterotypic 
positive but non matching responses by both ELISA and 
NT tests was more difficult, but did not exclude recent 
Coxsackie infection (A or B serotypes).
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The CBV IgM ELISA test is rapid and reliable, and 
gives reproducible results when used for routine 
diagnostic purposes. Because all 5 CBV antigens are 
used, the test is expensive and currently costs £5 per 
specimen when commercial antigens are used. Screening 
sera with one antigen, or an antigen cocktail, to cut 
costs is not yet feasible but is clearly desirable 
since demands for the test are mounting. The clinician 
benefits from receipt of a rapid result, which is 
totally adequate for the purposes of the clinical 
management of the patient, though the identification of 
the actual CBV serotype is of more relevance to the 
virologist and/or epidemiologist studying the viral 
aetiology of specific diseases. To this end, a 
greater specificity in the test may be obtainable with 
the use of monoclonal antibodies rather than by 
resorting to tedious virus concentration and 
purification procedures.
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CHAPTER 5
u - ANTIBODY CAPTURE ELISA 
FOR THE RAPID DIAGNOSIS 
OF ENTEROVIRUS INFECTIONS 
IN PATIENTS WITH 
ASEPTIC MENINGITIS.
1. Introduction.
Non-*bacterial aseptic 
meningitis (AM) continues to be a common sporadic or 
epidemic manifestation of enterovirus infections. Most 
of the 69 different enterovirus serotypes have been 
isolated from patients with AM, with the echoviruses 
being predominant (1).
The diagnosis of enterovirus infections, 
employing conventional virus isolation procedures, is 
usually not achieved until long after the patient has 
been discharged from hospital.(2). A survey carried 
out on 4073 patients with AM in the United States of 
America showed that as many as 3340 (82%) may remain 
virologically undiagnosed.(3).
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Early detection of enterovirus specific IgM, 
which will indicate recent or current infection, 
provides an attractive alternative diagnostic tool.
The CBV specific IgM ELISA test, as described in 
chapters 3 and 4, proved useful in the routine 
diagnosis of CBV infections in various clinical 
situations. However, this ELISA test has been shown to 
cross react with others of the enterovirus group, 
particularly Coxsackie A viruses and echoviruses. It 
was decided to exploit this disadvantage and apply this 
ELISA test to patients with aseptic meningitis.
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II PATIENTS AND METHODS.
Patients.
Between August and November 1985, 45 patients 
admitted to Monklands District General hospital with 
suspected aseptic meningitis were virologically 
investigated. Twenty six were male and 19 were 
female, and their ages ranged from 11 months to 49 
years (mean 21.7 years).
Virus isolation.
Samples of CSF and faeces, taken during the acute 
phase of illness, were inoculated into tube cultures 
(monolayers) of primary monkey kidney and MRC5 cells, 
according to the folowing protocol.
A 10% weight/volume emulsion of faeces in 
antibiotic-containing phosphate buffered saline 
(PBS;Dulbecco A with antibiotics) was prepared. This 
was allowed to stand at room temperature for 20 
minutes then centrifuged at 2500 r.p.m. for a further 
20 minutes. The resultant bacteria-free supernate was 
used to inoculate the cell cultures. CSF samples were 
inoculated untreated.
The inoculated tubes were examined every two 
days for evidence of virus growth. Negative cultures 
were maintained for fourteen days before being 
considered negative. Positive and suspect cultures
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were frozen at -20°C and thawed once then 0.2ml of the 
fluid inoculated into two fresh tubes of the same 
tissue. Viruses thus isolated were aliquoted and 
stored at -20°C prior to identification.
Virus isolates were identified by 
neutralisation tests using pooled and monospecific 
antisera as described by Grist et al, 1979. (4).
Methods
ELISA tests were used with the collected paired 
sera. The first taken soon after admission, the 
second three to seven days later, and these were tested 
for the presence of CBV IgM antibody using the u - 
antibody capture ELISA test described in chapter 3.
Routine CF tests were also performed to exclude 
non-enteroviral causes of illness in these patients.
| III Results.
Of the 45 patients studied, a total of 10(22%), 
yielded an enterovirus when using the conventional 
virus isolation procedures,/ 4 were isolated from 
faeces specimens only), whereas 30(67%) produced a j
I i
positive CBV IgM response in the ELISA test(Table 5.1.),
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Table 5.1 
Results of Enterovirus studies 
on 45 Patients with suspected 
Aseptic meningitis.
Specimen Total No. Examined No. Positive(%)
CSF 45 6a (13)
Faeces 39 10b (26)
Sera 14 single 9 (64)
31 pairs 21 (68)
CSF and Faeces 45(patients) 10 (22)
Sera 45(patients) 30 (67)
a All six patients with virus in the CSF had the same 
virus in their faeces.
b The isolates were B5(l), E5(5), E6(2), E7(l), and 
Ell(7).
All patients from whom a virus was isolated, from 
CSF or faecal samples were found to be CBV IgM 
positive. Fourteen single serum samples and 31
paired sera were examined, 9 of the single sera were 
CBV IgM positive, these samples having been taken 1-7 
days(mean 3.2 days) after admission. The 5 negative 
single sera had been sampled earlier in the illness, 
at 6 hours - 2 days (mean 1.05 days). Seventeen of 
the paired sera showed a significant rise, and 4 a
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significant fail in CBV IgM levels. The acute phase
sera of 16 of the 21 positive paired serum patients, 
taken on average 3 days after admission, gave a 
positive CBV IgM response, the 5 remaining patients 
whose acute phase sera were negative having been 
sampled earlier(mean 2.2 days) (Table 5.2.).
Table 5.2 
CBV IgM Positive responses 
21 paired sera.
Acute Convalescent
CBV IgM CBV IgM
Positive Negative Positive Negative
16 5 18 3(FT)*
Mean 3 days 2.2 days
days after (l-5days) (8hrs-4days) (5-21days)(13- 
onset of symptoms. 36days)
* The three negative sera were from patients who gave 
positive results on the acute sample only.
FT = falling titres fi.e.. from positive to negative1)
Heterotypic CBV IgM responses were common in this, 
group of patients (Table 5.3). No distinct pattern in 
the type of heterotypic response emerged either in 
relation to the age or to the sex of the patients or to 
the serotype of the virus isolated (3 patients had 
echovirus 5 isolated, 4 had echovirus 11 isolated).
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Strong positive reactions in the ELISA test, as 
reflected by high OD values indicating high levels of 
IgM, were detected more frequently here than were 
obtained from patients with other illnesses with CBV 
etiology i.e., myopericarditis or Bornholm disease.
Table 5.3
Responses in 30 Patients 
with Aseptic Meningitis 
CBV IgM positive.
Monotypic Heterotypic
No. of sera 7 23(77%)
Relative strength + +++
as reflected by OD values.
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On completion of these laboratpry investigations, 
the final clinical diagnoses of these patients was 
revealed and compared with the virological findings, 
(Table 5.4). No virological diagnoses were made on 
the basis of the CF tests.
The group with aseptic meningitis had CSF 
lymphocyte cell counts ranging from 6 to 390 cells per 
ml (mean 98 cells).
Those with meningism had cell counts of <1 cells per 
ml. Although headache was a feature in most of the 
miscellaneous group of patients, none had meningism, 
and the one patient with a positive CBV IgM response in 
this group had xanthochromic staining of the CSF.
Table 5.4
Final clinical diagnosis 
and enterovirus results.
Clinical diagnosis. 
Aseptic meningitis 
Meningism 
Miscellaneous
No. Patients
16
21
8
No. Positive
18 (86%)
11 (69%)
1 (12%)
Total 45 30 (67%)
Footnote
Other viruses and microbes tested for by CF tests 
Mumps (S and V), measles, herpes simplex, 
varicella zoster, cytomegalovirus,
pneumoniae and Leptospira patoc.
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V DISCUSSION.
Enterovirus infections are usually 
under diagnosed, either because of the inadequacies of 
type and of timing of specimens submitted for 
investigation, or -l. sensitivity of the virus or 
antigen detection system used. Serological diagnosis 
has not hitherto been practicable because of the large 
numbers of enterovirus serotypes involved. The results 
reported in this chapter suggest that many of these 
difficulties can be readily overcome by using the u - 
antibody capture Coxsackie B virus IgM ELISA test.
By exploiting the well recognised cross-reactivity of 
this test with the Coxsackie A virus and echovirus 
groups 5,6 (see chapter 3 ) an enterovirus infection 
was diagnosed in 67% of patients with suspected aseptic 
meningitis, compared with only 22% when using 
conventional virus isolation procedures. Not only 
did the described ELISA test increase the detection 
rate of enterovirus infections, but it also provided 
evidence of systemic infection in these patients as 
well. While isolation of virus from CSF is deemed 
diagnostic, isolation of virus from faeces is of 
considerably less significance, particularly in 
children.
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Using this ELISA test a rapid result is possible, 
and a report may be issued within forty eight hours of 
receipt of the patient's serum at the laboratory. 
Although CBV IgM responses were detected in acute phase 
single serum samples, paired sera taken within a three 
to five day time interval gave a more reliable result.
Significant rising or falling CBV IgM levels 
indicative of current or recent enterovirus infection 
were detected in 21 (68%) of the 31 paired sera 
examined here. Although no specific control group was 
included, sera from 304 apparently healthy adults 
living in the same conurbation were sampled between 
January and August 1985. When tested (see chapter 3) 
only 27 (9%) were CBV IgM positive, and none gave the 
high levels of CBV IgM seen in aseptic meningitis 
patients.
Chapter 3 describes the use of the CBV IgM ELISA 
test in routine diagnosis with more than 1000 patients 
with cardiac and other illnesses of suspected CBV 
aetiology. Two major differences in the CBV IgM 
response were noted in those patients with suspected 
aseptic meningitis. Firstly, a higher frequency of 
heterotypic cross reactions was observed, and these 
appeared not to be age related.
Studies by Banatvala et al (5) of juvenile onset 
diabetes mellitus have shown that monotypic responses
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predominate in such children. In this study, of the 
seven children aged under ten years, 6 showed a 
heterotypic response. Secondly, strongly positive CBV 
IgM responses were detected more often in the aseptic 
meningitis patients. These differences in type and
magnitude of response may be explained if echoviruses 
rather than Coxsackie B virus infections were being 
detected, a hypothesis supported by the viruses 
isolated.
Moreover, the acute onset and rapid spread of virus to 
the central nervous system in this group of patients 
may invoke a more rapid and stronger IgM response, in 
contrast to patients with enteroviral heart disease 
which is generally recognised as a late manifestation 
of virus infection.
The capability of this ELISA test to produce a 
rapid and reproducible result has added a new dimension 
to the serological diagnosis of enterovirus infections, 
especially because clinicians receive a report within 
two days of submission of specimens, a positive result 
being reassuring to the patient and helpful in clinical 
management. The limitation of the test in identifying 
the infecting serotype is of more significance for the 
virologist and epidemiologist than the clinician.
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CHAPTER 6.
CONCLUSIONS.
Serology is at the present time the most feasible 
way of investigating the possible CBV etiology of 
myopericarditis, ME and similar associated syndromes 
where the majority of patients seek medical advice 
after virus excretion has ceased, and hence where virus 
isolations are mostly unreliable.
Neutralisation tests are better suited to 
epidemiological surveys than diagnostic tests as the 
significance of static high titres is difficult to 
assess, and the detection of significant rising or 
falling titres is rare.
The introduction of the CBV IgM ELISA test which 
is described here has added a new dimension to the 
serological diagnosis of enterovirus infections. The 
detection of CBV specific IgM here has been considered 
to indicate a recent or persisting CBV infection, 
though the CBV IgM ELISA has not been found to be 
totally specific for CBV's, with cross reactions 
occurring with sera from patients with other proven 
non-polio enterovirus(NPEV) infections. However, the 
fact that enterovirus IgM is present is sufficient in 
many cases for a presumptive diagnosis to be made.
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The probability of a CBV etiology can be increased by 
using a confirmatory neutralisation test. Sera giving 
matching positive IgM and high neutralisation test 
titres are considered, without doubt, the result of a 
specific CBV infection.
1. Current uses of the CBV IgM ELISA test.
The use of the CBV IgM ELISA on its own to 
diagnose current or recent CBV infections should be 
discouraged, since back-up neutralisation tests and 
constant monitoring of antibody levels in the community 
is required if the results are to be interpreted 
sensibly. The occurrence of a CBV epidemic, as 
happened in 1985, when CBV type 5 was predominant in 
the West of Scotland, does lead to increased levels of 
specific antibody in the community (1). This in turn 
lead to difficulties in the interpretation of the test 
results in relation to the cardiac- and ME-associated 
disease being investigated at that time.
A diagnostic serology laboratory regimen to screen 
patients sera, either as an aid to specific diagnoses 
or as part of studies into the etiology of diseases of 
unknown cause, by the CBV IgM ELISA test and with 
confirmatory NTs carried out on the positives, has been 
described in chapter 4. This type of regimen is best 
suited to larger laboratories where large numbers of 
sera are being tested, because on price alone the cost
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per sample of screening small numbers would be 
prohibitive (see costs of tests table 6.1)
Table 6.1.
The breakdown of costs of the CBV IgM ELISA 
and the CBV neutralisation test(NT).
On a batch of 24 sera.
Cost in £'s of:-
REAGENTS/CONSUMABLES
Microtitre plates
Media/chemicals
Antigens
Antiserum
Conjugate
Stationary
Cells
Subtotal
Technical time
Cost (£6.83 per hour)
Total
Cost per sample
ELISA
3.50
15.00 
81.00(20.00)* 
13 .00
3.00
1.50 
0.00
117.00
4.5 hrs 
£30.73 
£147.73 
£6.16
NT
9.20
17.00 
0.00 
1.80 
0.00
1.00
20.00
49.00
7.5 hrs 
£51.23 
£100.23 
£4.18
* The use of In-house antigens as described in chapter 
3, pages 75-87 reduces the cost of ELISA reagents by 
£61.00, giving a Subtotal of £86.73. However it 
increases the technical time by 3 hours ie.£20.49 
giving a final Total of £107.22, which is £4.46 per 
sample.
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The approximate reagent cost of £5 per serum 
sample in the ELISA test adds up to £25000 when 5000 
samples per year are being tested. This was the level 
of requests generated when the CBV IgM ELISA was 
introduced into routine use in the Regional Virus 
laboratory^Ruchil1. An increase in expenditure of 
this magnitude could not be met from the existing 
laboratory budget and financial support had to be 
secured from other sources i.e., other Health 
Authorities served by this laboratory.
The use of in-house antigens reduced the financial 
burden considerably.
The application of this CBV IgM ELISA, to the 
rapid diagnosis of aseptic meningitis taking full 
advantage of the reported cross-reactions, is the most 
exciting development reported here. This test has 
many advantages over conventional virus isolation, 
e.g.,
1. the results are available sooner, and normally 
within 48 hours of receipt of the specimen.
2. it is a more sensitive test in that a much higher 
rate of 67% positive diagnoses are achieved as 
compared with 22% when using conventional virus 
isolation procedures;
3. it is a more reliable marker of causal association 
of illness than is isolation from faeces, as a positive
/
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result is consistent with a systemic infection and not 
merely viral carriage;
4. there is no need to use precious CSF samples to make 
a diagnosis.
There are a number of points worthy of 
consideration that accrue from using this test as a 
diagnostic tool when suspecting aseptic meningitis
1. it does not identify the serotype of the infecting 
virus, although this is of more interest to the 
virologist and epidemiologist than to the front line 
clinician;
2. it cannot detect poliovirus IgM and although aseptic 
meningitis resulting from poliovirus infection is rare 
in this country, isolation samples may still be 
additionally required to guard against this 
possibility, and they would certainly be needed if the 
CBV IgM ELISA test was used in countries where 
poliovirus infections were more common;
3. the test is very expensive unless large batches 
(minimum 24) of sera are tested, so that it would have 
to be in routine use for purposes other than aseptic 
meningitis to be financially feasible.
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2. Future developments.
1. A single antigen screening test which would 
reduce costs and increase the use of the CBV IgM ELISA 
test in the diagnosis of aseptic meningitis is 
desirable. VP1 produced as a synthetic peptide would 
appear to be a feasible option, as a monoclonal 
antibody raised against VP1 has already been used to 
detect circulating immune complexes in patients with ME 
(2).
2. The use of the CBV IgM ELISA test in the 
investigation of the etiological agents of ME and other 
neuro-muscular diseases of unknown etiology and non- 
familial and clustering epidemiology, e.g., Motor 
Neuron disease, should be done in conjunction with the 
current research into non-cell culture based methods 
for the detection of viral antigens or nucleic acid 
sequences, e.g., polymerase chain reaction (PCR) for 
the detection of CBV specific RNA in tissue biopsies 
and other samples.
The association of CBV's with Postviral Fatigue 
Syndromes (PVS) is far from proven, but enough 
information in now available to suggest that such an 
association does exist. The application of techniques 
such as PCR and monoclonal antibodies for detecting 
circulating immune complexes containing VP1, to the 
investigation of PVSs should lead to a better
137
understanding of the role of enteroviruses in general 
and CBV's in particular, to these. The correlation of 
the results using this alternative technology with the 
CBV IgM ELISA results will clearly serve to establish 
the diagnostic value of the CBV IgM ELISA test.
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